licochalcone a profile

licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Glycyrrhiza	genus	A genus of leguminous herbs or shrubs whose roots yield GLYCYRRHETINIC ACID and its derivative, CARBENOXOLONE.[MeSH]	Fabaceae	The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

ID Source	ID
PubMed CID	5318998
CHEMBL ID	139702
CHEBI ID	174541
CHEBI ID	125689
SCHEMBL ID	114042
MeSH ID	M0192729

Synonym
CHEBI:174541
(e)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
2-propen-1-one, 3-(5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (e)-
3-dimethylallyl-4,4'-dihydroxy-6-methoxychalcone
(2e)-3-(5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-2-propen-1-one
(e)-3-[5-(1,1-dimethylallyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
58749-22-7
licochalcone a
2-propen-1-one, 3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)- (e)-
HSCI1_000078
LMPK12120424
CHEBI:125689
licoagrochacone a
CHEMBL139702 ,
(e)-3-[5-(1,1-dimethyl-allyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxy-phenyl)-propenone
(e)-3-(4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
bdbm50068270
3-(4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
3-[5-((e)-1,1-dimethyl-allyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxy-phenyl)-propenone
jtv5467968 ,
unii-jtv5467968
S7828
BRD-K99667445-001-01-4
CCG-208030
SCHEMBL114042
licochalcone a [who-dd]
licochalcone a [mi]
2-propen-1-one, 3-(5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (2e)-
87080-27-1
licochalcone-a
AC-34241
Q-100677
AKOS026673964
licochalcone a, >=96.0% (hplc)
HY-N0372
EX-A1193
CS-5603
(2e)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
AS-74730
licochalconea
KAZSKMJFUPEHHW-DHZHZOJOSA-N
mfcd01417903
BCP08941
Q1644097
2-propen-1-one,3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-, (2e)-
chalcone base + 2o, 1meo, 1prenyl or licochalcone a (not validated)
A902621
(2e)-3-[5-(1,1-dimethyl-2-propen-1-yl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-2-propen-1-one
DTXSID10904181
L0261
e)-3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-2-propen-1-one

Excerpt	Reference	Relevance
"Licochalcone A (Lico A) is a natural flavonoid belonging to the class of substituted chalcone that has various biological effects. "	( Licochalcone A inhibits MAS-related GPR family member X2-induced pseudo-allergic reaction by suppressing nuclear migration of nuclear factor-κB. Bai, H; Hu, S; Jing, H; Wang, J; Wang, N; Xue, Z; Zeng, Y; Zhang, Y, 2021)	3.51
"Licochalcone A (LicA) is a flavonoid found in licorice; previous studies have shown that LicA can reduce blood glucose, blood lipids and improve insulin resistance."	( Impact of licochalcone A on the progression of diabetic nephropathy in type 2 diabetes mellitus of C57BL/6 mice. Chen, Y; Gao, Q; Li, T; Luo, Z; Su, G; Zhao, Y, 2021)	1.75
"Licochalcone A (LicA) is a primary active compound of licorice root and is known to have medicinal effects, such as antioxidant, antibacterial, antiviral, and anticancer effects."	( Licochalcone A inhibits cell growth through the downregulation of the Hippo pathway via PES1 in cholangiocarcinoma cells. Cao, F; Li, J; Li, P; Li, PP; Liu, J; Miao, Y; Xu, KD, 2022)	2.89
"Licochalcone A (LA) is a chalcone flavonoid of "	( Licochalcone A activation of glycolysis pathway has an anti-aging effect on human adipose stem cells. Liu, H; Shen, H; Wang, H; Wu, Y; Zhu, J, 2021)	3.51
"Licochalcone A (LCA) is a flavonoid isolated from Glycyrrhiza uralensis Fisch that has shown promising therapeutic effects in various cancers. "	( Licochalcone A induces G2/M phase arrest and apoptosis via regulating p53 pathways in esophageal cancer: In-vitro and in-vivo study. Chen, Y; Deng, L; He, C; Liu, J; Qian, D; Ren, Q; Wang, L; Zhang, Q, 2023)	3.8
"Licochalcone A (Lico-A) is a flavonoid compound derived from the root of the Glycyrrhiza species, a plant commonly used in traditional Chinese medicine. "	( Licochalcone A: A Potential Multitarget Drug for Alzheimer's Disease Treatment. Auladell, C; Bicker, J; Camins, A; Cano, A; Ettcheto, M; Fortuna, A; Olloquequi, J; Paz, C; Sánchez-Lopez, E; Ureña, J; Verdaguer, E, 2023)	3.8
"Licochalcone A is a phenolic chalcone compound and a characteristic chalcone of Glycyrrhiza glabra L."	( Licochalcone A inhibits proliferation and promotes apoptosis of colon cancer cell by targeting programmed cell death-ligand 1 via the NF-κB and Ras/Raf/MEK pathways. Jin, C; Jin, H; Jin, X; Li, M; Liu, X; Ma, J; Piao, L; Ri, M; Wang, J; Xing, Y; Xu, G; Zhang, Z; Zuo, H, 2021)	2.79
"Licochalcone A (LicA) is a chalcone extracted from liquorice which has been used as a traditional Chinese medicine for many generations. "	( Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway. Chen, M; Liu, S; Sun, Q; Wang, Y; Wu, J; Zhang, X; Zou, X, 2018)	3.37
"Licochalcone A (Lico A) is a characteristic chalcone isolated from licorice root which is widely recognized in traditional Chinese medicine for the ability of anti-inflammatory, antioxidant, anti-parasitic and anti-cancer. "	( NF-κB and Nrf2 pathways contribute to the protective effect of Licochalcone A on dextran sulphate sodium-induced ulcerative colitis in mice. Cao, L; Gao, L; Huo, X; Liu, D; Ni, H; Zhang, J, 2018)	2.16
"Licochalcone A (LA) is a major phenolic ingredient of Glycyrrhiza plant. "	( Licochalcone A regulates hepatic lipid metabolism through activation of AMP-activated protein kinase. Chung, SH; Jo, HK; Kim, DY; Kim, GW; Kim, SJ; Quan, HY, 2013)	3.28
"Licochalcone A (Lico A) is a major and biogenetically characteristic chalcone isolated from the root of Xinjiang liquorice, Glycyrrhiza inflata."	( Attenuation of allergic airway inflammation in a murine model of asthma by Licochalcone A. Chu, X; Guan, M; Jiang, L; Liu, D; Wang, D; Wei, J; Wei, M; Xie, X; Yang, X, 2013)	2.06
"Licochalcone A (Lico-A) is a natural phenol licorice compound with multiple bioactivities, including anti-inflammatory, anti-microbial, anti-fungal and osteogenesis-inducing properties. "	( Licochalcone A induces apoptosis in KB human oral cancer cells via a caspase-dependent FasL signaling pathway. Cho, SS; Im, HJ; Kim, CS; Kim, DK; Kim, JS; Kim, SG; Lee, SY; Moon, SM; Oh, JS; Park, MR; Yoon, G; You, JS, 2014)	3.29
"Licochalcone A (LicA) is a characteristic chalcone of licorice, which is the root of Glycyrrhiza inflate."	( Licochalcone A suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4/JNK via NF-κB mediated urokinase plasminogen activator expression. Bau, DT; Hsiao, PC; Hsieh, SC; Hsieh, YH; Ling, CL; Pai, CL; Tsai, JP; Yang, SF, 2014)	2.57
"Licochalcone A (LCA) is a natural product derived from the roots of Glycyrrhiza inflata exhibiting a wide range of bioactivities such as antitumor, anti-oxidant and anti-bacterial effects. "	( Licochalcone A induces apoptosis in malignant pleural mesothelioma through downregulation of Sp1 and subsequent activation of mitochondria-related apoptotic pathway. Chae, JI; Cho, JH; Cho, JJ; Cho, YS; Kim, KH; Shim, JH; Yoon, G, 2015)	3.3
"Licochalcone A (LicoA) is a prominent member of the chalcone family and can be isolated from licorice root."	( Licochalcone A, a polyphenol present in licorice, suppresses UV-induced COX-2 expression by targeting PI3K, MEK1, and B-Raf. Heo, YS; Kang, H; Kang, YG; Kim, JE; Kim, JR; Lee, E; Lee, KW; Park, JS; Seo, SG; Son, JE; Song, NR, 2015)	2.58
"Licochalcone A (LCA) is a major bioactive compound in traditional Chinese herbal liquorice that possesses multiple pharmacological activities. "	( Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice. Ge, GB; He, W; He, YQ; Hou, J; Ning, J; Wu, JJ; Xin, H; Xu, W, 2015)	2.12
"Licochalcone A (LCA) is a major bioactive compound in Licorice, a widely used herbal medicine. "	( Assessment of the inhibition potential of Licochalcone A against human UDP-glucuronosyltransferases. Ge, GB; He, W; Hong, JY; Li, Y; Qi, XY; Wang, XX; Wu, JJ; Xin, H; Xu, W; Yang, L, 2016)	2.14
"Licochalcone A (LCA) is a characteristic chalcone that is found in licorice, which is a traditional medicinal plant. "	( Antioxidative and anticancer properties of Licochalcone A from licorice. Chen, X; Guo, N; Liu, Z; Meng, R; Shi, C, 2017)	2.16
"Licochalcone A is a major component of Xinjiang licorice, Glycyrrhiza inflata."	( Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway. Funakoshi-Tago, M; Furusawa, J; Inoue, H; Kasahara, T; Mashino, T; Sonoda, Y; Tago, K, 2009)	1.34
"Licochalcone A is a major and biogenetically characteristic chalcone isolated from G."	( Licochalcone A potently inhibits tumor necrosis factor alpha-induced nuclear factor-kappaB activation through the direct inhibition of IkappaB kinase complex activation. Funakoshi-Tago, M; Itoh, H; Kasahara, T; Mashino, T; Sonoda, Y; Tago, K; Tanabe, S, 2009)	2.52
"Licochalcone A (Lico A) is a retrochalcone isolated from the root of Xinjiang liquorice and has been reported to exhibit various biological activities such as anti-inflammatory activity."	( Licochalcones suppress degranulation by decreasing the intracellular Ca2+ level and tyrosine phosphorylation of ERK in RBL-2H3 cells. Aizu-Yokota, E; Funakoshi-Tago, M; Inoue, H; Kasahara, T; Sonoda, Y; Tanifuji, S, 2010)	1.08

Excerpt	Reference	Relevance
"Licochalcone A has a significant effect on biofilm formation, while both licochalcone A and glabridin prevented yeast-hyphal transition in C."	( Effect of licorice compounds licochalcone A, glabridin and glycyrrhizic acid on growth and virulence properties of Candida albicans. Grenier, D; Messier, C, 2011)	1.38
"Licochalcone A (LicA) has been reported to possess antitumor properties. "	( Licochalcone A inhibits the invasive potential of human glioma cells by targeting the MEK/ERK and ADAM9 signaling pathways. Chiou, HL; Hsieh, YH; Hsu, JC; Hsu, WH; Huang, CF; Liu, CJ; Yang, SF, 2018)	3.37
"Licochalcone A has a significant effect on biofilm formation, while both licochalcone A and glabridin prevented yeast-hyphal transition in C."	( Effect of licorice compounds licochalcone A, glabridin and glycyrrhizic acid on growth and virulence properties of Candida albicans. Grenier, D; Messier, C, 2011)	1.38
"Licochalcone A (LA) has been shown to exert multiple pharmacological effects, including anti-inflammatory, antiparasitic, antifungal, anticancer, and osteogenic activities. "	( Licochalcone A prevents adipocyte differentiation and lipogenesis via suppression of peroxisome proliferator-activated receptor γ and sterol regulatory element-binding protein pathways. Baek, NI; Chung, SH; Quan, HY, 2012)	3.26

Excerpt	Reference	Relevance
"Licochalcone A failed to inhibit the activity of TEL-Jak2, however, this induced apoptosis of TEL-Jak2-transformed cells with a much lower concentration in the absence of IL-3 than in the presence of IL-3."	( Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transformation through the specific inhibition of Stat3 activation. Funakoshi-Tago, M; Inoue, H; Iwata, S; Kasahara, T; Mashino, T; Nishizawa, C; Sonoda, Y; Tago, K; Takahashi, K, 2008)	2.51
"Licochalcone A did not inhibit the germination of heat-treated spores of B."	( Antibacterial activity of licochalcone A against spore-forming bacteria. Katsura, H; Kobayashi, M; Tokuriki, N; Tsukiyama, R, 2002)	1.34

Excerpt	Reference	Relevance
"Treatment with licochalcone A significantly increases ERK1/2, p38, and JNK1/2 activation."	( Licochalcone A induces apoptotic cell death via JNK/p38 activation in human nasopharyngeal carcinoma cells. Chen, PN; Chuang, CY; Ho, HY; Hsin, CH; Lin, CW; Tang, CM; Weng, CJ; Yang, SF, 2019)	2.3
"Pretreatment with licochalcone A enhanced the relaxant effect of forskolin, an adenylyl cyclase activator, on the contraction in a similar manner to 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase (PDE) inhibitor."	( Antispasmodic activity of licochalcone A, a species-specific ingredient of Glycyrrhiza inflata roots. Akao, T; He, JX; Nagai, H; Tani, T, 2007)	0.96

Excerpt	Reference	Relevance
" Pharmacokinetic parameters of losartan and EXP-3174 were determined after oral administration of losartan (9 mg/kg) to rats in the presence or absence of licochalcon A (0."	( Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Choi, DH; Choi, JS, 2013)	0.39
" The pharmacokinetic parameters of nifedipine and/or dehydronifedipine were determined after oral and intravenous administration of nifedipine to rats in the absence (control) and presence of licochalcone A (0."	( Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A. Choi, DH; Choi, JS, 2014)	0.98
" Pharmacokinetic and tissue distribution studies showed that LCA-Liposomes could improve the availability of LCA in the blood and tissues, whereas during pharmacodynamics studies, the liposome effectively improved the therapeutic effect of LCA on CRF mice by potentially protecting the renal tissues while exhibiting antioxidant activity."	( Preparation, characterization, pharmacokinetics, and antirenal injury activity studies of Licochalcone A-loaded liposomes. Adu-Frimpong, M; Chen, L; Ji, H; Liu, J; Toreniyazov, E; Wang, Q; Xu, X; Yang, Y; Yu, J; Zhu, Z, 2022)	0.94

Excerpt	Reference	Relevance
" A few potent chalcones were selected for their antimalarial interaction in combination with artemisinin in vitro."	( Antimalarial pharmacodynamics of chalcone derivatives in combination with artemisinin against Plasmodium falciparum in vitro. Awasthi, SK; Bhasin, VK; Bhattacharya, A; Mishra, LC; Sharma, M, 2009)	0.35

Excerpt	Reference	Relevance
" Consequently, the absolute bioavailability of losartan in the presence of licochalcon A increased significantly (2."	( Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Choi, DH; Choi, JS, 2013)	0.39
" Treatment with LigC alone did not induce NQO1 in vivo most likely due to its conversion to LigF, extensive metabolism, and its low bioavailability in vivo."	( Induction of NAD(P)H:Quinone Oxidoreductase 1 (NQO1) by Glycyrrhiza Species Used for Women's Health: Differential Effects of the Michael Acceptors Isoliquiritigenin and Licochalcone A. Bolton, JL; Chen, SN; Dietz, BM; Dong, H; Hajirahimkhan, A; Lantvit, DD; Li, G; Nikolić, D; Pauli, GF; Simmler, C; van Breemen, RB, 2015)	0.61
"The aim of this study was to develop licochalcone A-loaded self-microemulsifying drug delivery system (LCA-SMEDDS) to improve bioavailability and anti-hyperuricemic activity of hydrophobic natural compound licochalcone A (LCA)."	( SMEDDS for improved oral bioavailability and anti-hyperuricemic activity of licochalcone A. Adu-Frimpong, M; Ji, H; Liu, J; Toreniyazov, E; Wang, Q; Xu, X; Yang, Y; Yu, J; Zhu, Z, )	0.63
" In conclusion, LCA-Liposomes could effectively improve the bioavailability of LCA and provide platform for the development of LCA-related functional products."	( Preparation, characterization, pharmacokinetics, and antirenal injury activity studies of Licochalcone A-loaded liposomes. Adu-Frimpong, M; Chen, L; Ji, H; Liu, J; Toreniyazov, E; Wang, Q; Xu, X; Yang, Y; Yu, J; Zhu, Z, 2022)	0.94

Excerpt	Relevance	Reference
" Finally, the in vivo mice bearing a SiHa xenograft, LicA dosed at 10 or 20 mg/kg significantly inhibited tumor growth."	( Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells. Hsieh, YH; Hsueh, JT; Lee, CH; Lin, CL; Tsai, JP; Ying, TH, 2015)	1.86

Class	Description
chalcones	A ketone that is 1,3-diphenylpropenone (benzylideneacetophenone), ArCH=CH(=O)Ar, and its derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)	IC50 (µMol)	60.6820	0.0035	0.5274	5.1760	AID1647134; AID1647135; AID1647136
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	109.0850	0.0002	2.3185	10.0000	AID1668498; AID1668499; AID1668500; AID1668501
Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)	IC50 (µMol)	19.1000	0.0005	3.4984	9.7600	AID1624911; AID447165; AID598810
UDP-glucuronosyltransferase 1A1	Homo sapiens (human)	IC50 (µMol)	0.9700	0.3000	3.2580	7.3000	AID1662435
Multidrug resistance-associated protein 1	Homo sapiens (human)	IC50 (µMol)	56.4875	0.0015	3.7110	9.6600	AID1668482; AID1668483; AID1668484; AID1668485
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	2.2717	0.0040	1.9666	10.0000	AID1668390; AID1668391; AID1668392; AID1668393; AID1668406; AID1668407; AID1668408; AID1668409; AID1668422; AID1668423; AID1668424; AID1668425; AID1668438; AID1668439; AID1668440; AID1668441; AID1668454; AID1668455; AID1668456; AID1668457; AID1668466; AID1668467; AID1668468; AID1668470
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)	Kd	21.8733	2.8100	2.8100	2.8100	AID1647129; AID1647130; AID1647131
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	EC50 (µMol)	14.0000	0.0054	0.4220	3.2000	AID1668342
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
glyoxylate cycle	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
tricarboxylic acid cycle	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
isocitrate metabolic process	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
2-oxoglutarate metabolic process	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
glutathione metabolic process	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
response to oxidative stress	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
female gonad development	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
response to steroid hormone	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
regulation of phospholipid catabolic process	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
regulation of phospholipid biosynthetic process	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
NADP metabolic process	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of JUN kinase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein dephosphorylation	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
insulin receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
regulation of signal transduction	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of signal transduction	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
actin cytoskeleton organization	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
regulation of endocytosis	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
endoplasmic reticulum unfolded protein response	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
regulation of intracellular protein transport	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cellular response to unfolded protein	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
peptidyl-tyrosine dephosphorylation	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
IRE1-mediated unfolded protein response	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
insulin receptor recycling	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of MAP kinase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
regulation of type I interferon-mediated signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STAT	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
positive regulation of protein tyrosine kinase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein response	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein response	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
positive regulation of receptor catabolic process	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
liver development	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
bilirubin conjugation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
acute-phase response	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to nutrient	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
steroid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
animal organ regeneration	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to lipopolysaccharide	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to starvation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
negative regulation of steroid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
flavone metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
biphenyl catabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to ethanol	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to glucocorticoid stimulus	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to estradiol stimulus	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
leukotriene metabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
response to xenobiotic stimulus	Multidrug resistance-associated protein 1	Homo sapiens (human)
cobalamin transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid biosynthetic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
cellular response to oxidative stress	Multidrug resistance-associated protein 1	Homo sapiens (human)
heme catabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
phospholipid translocation	Multidrug resistance-associated protein 1	Homo sapiens (human)
positive regulation of inflammatory response	Multidrug resistance-associated protein 1	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
cell chemotaxis	Multidrug resistance-associated protein 1	Homo sapiens (human)
transepithelial transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
cyclic nucleotide transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid translocation	Multidrug resistance-associated protein 1	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 1	Homo sapiens (human)
cellular response to amyloid-beta	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
lipid transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid biosynthetic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate metabolic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transmembrane transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transepithelial transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
renal urate salt excretion	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
export across plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
cellular detoxification	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
magnesium ion binding	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
isocitrate dehydrogenase (NADP+) activity	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
protein binding	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
identical protein binding	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
protein homodimerization activity	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
cadherin binding	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
NADP binding	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
NAD binding	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
RNA binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein tyrosine phosphatase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
insulin receptor binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
zinc ion binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
enzyme binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein kinase binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
receptor tyrosine kinase binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cadherin binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein phosphatase 2A binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
enzyme inhibitor activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
steroid binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type vitamin B12 transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
cytoplasm	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
peroxisome	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
peroxisomal matrix	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
cytosol	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
secretory granule lumen	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
extracellular exosome	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
tertiary granule lumen	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
ficolin-1-rich granule lumen	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
cytosol	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
mitochondrion	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
peroxisome	Isocitrate dehydrogenase [NADP] cytoplasmic	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cytoplasm	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
mitochondrial matrix	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
early endosome	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
endoplasmic reticulum	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cytosol	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
mitochondrial crista	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
endosome lumen	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
sorting endosome	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membrane	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein-containing complex	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
endoplasmic reticulum	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cytoplasm	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
early endosome	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
plasma membrane	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
perinuclear region of cytoplasm	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum chaperone complex	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cytochrome complex	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basal plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
lateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
extracellular exosome	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (371)

Assay ID	Title	Year	Journal	Article
AID255774	In vitro antimalarial activity against Plasmodium falciparum 3D7	2005	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21	Conformationally restricted anti-plasmodial chalcones.
AID1647129	Binding affinity to IDH1 (unknown origin) by surface plasmon resonance assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668488	Effect on etoposide-induced cytotoxicity against HEK293 cells assessed as fold change in etoposide IC50 at 1 uM after 72 hrs by CCK8 assay relative to etoposide IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463947	VRT (0 to infinity) in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1647164	Induction of apoptosis in human HT1080 cells assessed as viable cells at 20 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 95.9%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1372442	Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 20 mg/kg, po treated with ammonia 1 hr before and 1 hr after test compound dosing measured for 3 mins	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Antitussive and expectorant activities of licorice and its major compounds.
AID1668464	Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668347	Induction of apoptosis in human S1-M1-80 cells harboring ABCG2 (unknown origin) assessed as necrotic cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 0.3%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647148	Induction of cell cycle arrest in human HT1080 cells assessed accumulation at S phase at 5 uM incubated for 24 hrs by flow cytometric analysis (Rvb = 52.69%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668413	Effect on mitoxantrone-induced cytotoxicity against human H460 cells assessed as fold change in mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668367	Downregulation of ABCG2 expression in human S1-M1-80 cells at 0.5 to 3 uM incubated for 72 hrs by Western blot analysis	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668378	Modulation of human ABCB1 expressed in HEK293/MDR19 cells assessed as increase in intracellular calcein-AM accumulation at 20 uM incubated for 10 mins by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668468	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 50.66 +/- 6.88 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310800	Growth inhibition of Helicobacter pyroli	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID310789	Antibacterial activity against Bacillus coagulans	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668441	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID312863	Inhibition of fumarate reductase in permeabilized Leishmania major promastigotes	2008	Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3	2-(3-aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial chemotype.
AID1516837	Antifungal activity against Candida albicans	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Recent advances in natural antifungal flavonoids and their derivatives.
AID1188432	Antimalarial activity against Plasmodium falciparum asexual blood stage forms	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Recent developments in biological activities of chalcones: a mini review.
AID1668510	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as potentiation of topotecan-induced cytotoxicity after 72 hrs by CCK8 assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668381	Cytotoxicity against human NCI-H460/MX20 cells harboring ABCG2 after 72 hrs by MTT assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1752770	Cytotoxicity against CHO-K1 cells incubated for 24 hrs by colorimetric assay	2020	RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4	Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID549518	Inhibition of Influenza A H9N2 virus neuraminidase activity after 2 hrs by spectrofluorometry	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1668408	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 1160.60 +/- 365.72 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1484043	Inhibition of LPS-induced NF-kappaB (unknown origin) transactivation expressed in human SW480 cells administered 1 hr after LPS stimulation measured after 6 hrs by luciferase reporter gene assay	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1668363	Induction of apoptosis in human S1 cells assessed as viable cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 94.1%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID253015	Effect on bacterial membrane integrity was determined by using SYTO9 green fluorescent nucleic acid strain	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Cationic chalcone antibiotics. Design, synthesis, and mechanism of action.
AID1668439	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668440	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647161	Induction of apoptosis in human HT1080 cells assessed as early apoptotic cells at 10 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 0.63%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668394	Effect on topotecan-induced cytotoxicity against human H460 cells assessed as fold change in topotecan IC50 at 3 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1372435	Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 50 mg/kg, po treated with ammonia 1 hr before and 5 hrs after test compound dosing measured for 3 mins relative to control	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Antitussive and expectorant activities of licorice and its major compounds.
AID1668385	Cytotoxicity against HEK293 cells overexpressing human ABCG2 after 72 hrs by CCK8 assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1453616	Growth inhibition of human HepG2 cells at 10 uM after 24 hrs by MTS assay relative to control	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID310795	Antibacterial activity against Lactobacillus acidophilus	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1604228	Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 24 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID1484046	Antiproliferative activity against human A549 cells at 10 uM after 24 hrs by MTS assay relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1667213	Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 50 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1668478	Reversal of human ABCC1-mediated multidrug resistance in HEK293/MRP1 cells assessed as fold-change in etoposide IC50 at 3 uM after 72 hrs by CCK8 relative to etoposide IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310802	Antibacterial activity against methicillin-resistant Staphylococcus aureus OM505	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1395335	Antileishmanial activity against Leishmania major amastigotes infected in human peripheral blood monocyte-derived macrophages	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	A comprehensive review of chalcone derivatives as antileishmanial agents.
AID1647140	Reduction in 2 HG level in human HT1080 cells harboring IDH1-R132C mutation incubated for 48 hrs by LC-MS analysis relative to control	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668398	Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668340	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as fold change in mitoxantrone IC50 at 0.5 uM after 72 hrs by CCK8 assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668502	Effect on Colchicine-induced cytotoxicity against HEK293 cells assessed as fold change in colchicine IC50 at 2 uM after 72 hrs by CCK8 assay relative to colchicine IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310833	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1752769	Antischistosomal activity against male Schistosoma mansoni LE incubated for 24 hrs by MTT assay	2020	RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4	Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID1668500	Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as effect on colchicine-induced cytotoxicity at 1 uM by measuring colchine IC50 after 72 hrs by CCK8 assay (Rvb = 97.58 +/- 17.62 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668507	Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1372444	Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 20 mg/kg, po treated with ammonia 1 hr before and 5 hrs after test compound dosing measured for 3 mins	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Antitussive and expectorant activities of licorice and its major compounds.
AID1668423	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668344	Potentiation of topotecan-induced apoptosis in human S1-M1-80 cells harboring ABCG2 (unknown origin) assessed as late apoptotic cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 6%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668410	Effect on mitoxantrone-induced cytotoxicity against human H460 cells assessed as change in mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668345	Potentiation of topotecan-induced apoptosis in human S1-M1-80 cells harboring ABCG2 (unknown origin) assessed as early apoptotic cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 3%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668480	Reversal of human ABCC1-mediated multidrug resistance in HEK293/MRP1 cells assessed as fold-change in etoposide IC50 at 1 uM after 72 hrs by CCK8 relative to etoposide IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668353	Induction of apoptosis in human S1 cells assessed as early apoptotic cells at 10 uM incubated for 48 hrs in presence of topotecan by annexin V/propidium iodide staining based flow cytometry (Rvb = 2%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668465	Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668396	Effect on topotecan-induced cytotoxicity against human H460 cells assessed as fold change in topotecan IC50 at 1 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668414	Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1453614	Growth inhibition of human MCF7 cells at 10 uM after 24 hrs by MTS assay relative to control	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1668365	Downregulation of ABCG2 expression in human NCI-H460/MX20 cells at 0.5 to 3 uM incubated for 72 hrs by Western blot analysis	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310793	Antibacterial activity against Bacillus cereus	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668432	Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 9.21 +/- 1.45 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668435	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as fold-change in mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310807	Antibacterial activity against Enterococcus faecium	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1647166	Induction of apoptosis in human HT1080 cells assessed as late apoptotic cells at 20 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 2.48%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1647139	Cytotoxicity against human U87MG cells harboring wild type IDH1 incubated for 48 hrs	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1647157	Induction of apoptosis in human HT1080 cells assessed as early apoptotic cells at 5 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 0.63%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668366	Inhibition of ABCG2 (unknown origin)-mediated pheophorbide A efflux in H460-MX20 cells incubated for 1 hr by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463945	Apparent volume of distribution during terminal phase in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1484042	Inhibition of LPS-induced NF-kappaB (unknown origin) transactivation expressed in human SW480 cells at 10 uM administered 1 hr after LPS stimulation measured after 6 hrs by luciferase reporter gene assay relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1668392	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 1319.20 +/- 356.14 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668425	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID598810	Inhibition of recombinant human PTP1B using p-nitrophenyl phosphate as substrate after 30 mins	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Design, synthesis, and evaluation of bromo-retrochalcone derivatives as protein tyrosine phosphatase 1B inhibitors.
AID1668445	Effect on mitoxantrone-induced cytotoxicity against human S1 cells assessed as fold change in mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310798	Antibacterial activity against Streptococcus lactis	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668459	Effect on topotecan-induced cytotoxicity against HEK293 cells assessed as fold change in topotecan IC50 at 2 uM after 72 hrs by CCK8 assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668463	Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463942	MRT (0 to t) in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668454	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 201.31 +/- 25.89 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID447165	Inhibition of recombinant human PTP1B assessed as hydrolysis of p-nitrophenyl phosphate after 30 mins	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	Inhibitory effect of chalcones and their derivatives from Glycyrrhiza inflata on protein tyrosine phosphatase 1B.
AID1668373	Induction of Calcein-AM accumulation in HEK293 cells at 20 uM incubated for 10 mins by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668506	Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1662435	Induction of UGT1A1 (unknown origin) assessed as increase in intracellular acidic autophagy vesicles formation	2020	Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18	p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators.
AID1647143	Reduction in CDK1 protein expression in human HT1080 cells incubated for 48 hrs by Western blot analysis	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1752768	Antischistosomal activity against female Schistosoma mansoni LE incubated for 24 hrs by MTT assay	2020	RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4	Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID1668372	Induction of pheophorbide A accumulation in HEK293 cells at 20 uM incubated for 1 hr by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID549521	Inhibition of Clostridium perfringens neuraminidase	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1514101	Antileishmanial activity against Leishmania donovani promastigotes infected in hamster assessed as reduction in parasitic load in spleen at 20 mg/kg, ip treated for 6 consecutive days measured at day 8 post last dose by 3H-thymidine incorporation assay re	2018	European journal of medicinal chemistry, Dec-05, Volume: 160	Leishmania treatment and prevention: Natural and synthesized drugs.
AID1668343	Potentiation of topotecan-induced apoptosis in human S1-M1-80 cells harboring ABCG2 (unknown origin) assessed as necrotic cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 0.4%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668501	Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as effect on colchicine-induced cytotoxicity at 0.5 uM by measuring colchine IC50 after 72 hrs by CCK8 assay (Rvb = 97.58 +/- 17.62 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668494	Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as fold change in colchicine IC50 at 3 uM after 72 hrs by CCK8 relative to colchicine IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID732687	Antitubercular activity against Mycobacterium tuberculosis assessed as growth inhibition	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Syntheses of lipophilic chalcones and their conformationally restricted analogues as antitubercular agents.
AID310796	Antibacterial activity against Lactobacillus plantarum	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1647137	Antiproliferative activity against human HT1080 cells harboring IDH1-R132C mutation incubated for 48 hrs	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1061200	Antiinflammatory activity in RBL2H3 cells assessed as inhibition of degranulation	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID1668354	Induction of apoptosis in human S1 cells assessed as viable cells at 10 uM incubated for 48 hrs in presence of topotecan by annexin V/propidium iodide staining based flow cytometry (Rvb = 94.1%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647147	Induction of cell cycle arrest in human HT1080 cells assessed accumulation at G1 phase at 5 uM incubated for 24 hrs by flow cytometric analysis (Rvb = 31.67%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668473	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells assessed as fold change in mitoxantrone IC50 at 0.5 uM after 72 hrs by CCK8 assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668508	Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668446	Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 4.83 +/- 0.83 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310822	Inhibition of Leishmania donovani fumarate reductase in after 60 mins	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668470	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 50.66 +/- 6.88 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463924	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells assessed as cytoprotection against CCL4-induced cell injury by measuring increase in cell viability at 2.5 to 20 uM relative to untreated control	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID310797	Antibacterial activity against Enterococcus faecalis	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668351	Induction of apoptosis in human S1 cells assessed as necrotic cells at 10 uM incubated for 48 hrs in presence of topotecan by annexin V/propidium iodide staining based flow cytometry (Rvb = 0.2%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668453	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as fold-change in topotecan IC50 at 1 uM after 72 hrs by CCK8 relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1395338	Antileishmanial activity against Leishmania donovani MHOM/SD/00/1SD2D axenic amastigotes infected in human peripheral blood monocyte-derived macrophages after 48 hrs by [3H]-thymidine incorporation assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	A comprehensive review of chalcone derivatives as antileishmanial agents.
AID1668412	Effect on mitoxantrone-induced cytotoxicity against human H460 cells assessed as fold change in mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668452	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as fold-change in topotecan IC50 at 0.5 uM after 72 hrs by CCK8 relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID386909	Antibacterial activity against Escherichia coli ATCC 49696 after 20 hrs by microdilution assay	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Functionalized chalcones with basic functionalities have antibacterial activity against drug sensitive Staphylococcus aureus.
AID1667215	Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 12.5 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to contr	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1668493	Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668474	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668407	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 1160.60 +/- 365.72 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668456	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 201.31 +/- 25.89 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID245048	Minimum inhibitory concentration against Staphylococcus aureus ATCC 33591 (resistant to methicillin)	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Cationic chalcone antibiotics. Design, synthesis, and mechanism of action.
AID310792	Antibacterial activity against Clostridium sporogenes	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID386906	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Functionalized chalcones with basic functionalities have antibacterial activity against drug sensitive Staphylococcus aureus.
AID1668403	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as fold change in mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647144	Reduction in CDK2 protein expression in human HT1080 cells incubated for 48 hrs by Western blot analysis	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1453621	Inhibition of LPS-induced NF-kappaB transcription (unknown origin) expressed in human SW480 cells at 10 uM by luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1668415	Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647128	Ratio of inhibition of IDH1 R132C mutant (unknown origin) at 30 uM to inhibition of IDH1 (unknown origin) at 30 uM by enzymatic assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID310791	Antibacterial activity against Bacillus stearothermophilus	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668477	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1604234	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID538324	Inhibition of Plasmodium falciparum-mediated human hemoglobin degradation at 100 uM	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Reinvestigation of structure-activity relationship of methoxylated chalcones as antimalarials: synthesis and evaluation of 2,4,5-trimethoxy substituted patterns as lead candidates derived from abundantly available natural β-asarone.
AID310824	Growth inhibition of Leishmania major promastigotes assessed as [3H]thymidine incorporation	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668401	Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668475	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668342	Modulation of ABCG2 (unknown origin) expressed in High Five insect cell vesicle membrane assessed as stimulation of ATPase activity after 20 mins by colorimetric assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID251339	Percent lysis of human erythrocytes after exposed to test compound was measured as hemolysis	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Cationic chalcone antibiotics. Design, synthesis, and mechanism of action.
AID1463922	Cytotoxicity in human HepG2 cells expressing Nrf2/ARE-driven luciferase at 10 to 40 uM incubated for 6 hrs	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668368	Inhibition of ABCG2 (unknown origin)-mediated pheophorbide A efflux in human S1 cells incubated for 1 hr by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID549517	Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1668388	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as fold change in topotecan IC50 at 1 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668387	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as fold change in topotecan IC50 at 2 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID519607	Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1647153	Induction of cell cycle arrest in human HT1080 cells assessed accumulation at G1 phase at 20 uM incubated for 24 hrs by flow cytometric analysis (Rvb = 31.67%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668436	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as fold-change in mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310816	Inhibition of Leishmania major succinate dehydrogenase	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668495	Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as fold change in colchicine IC50 at 2 uM after 72 hrs by CCK8 relative to colchicine IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668400	Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647141	Reduction in CDK1 mRNA level in human HT1080 cells incubated for 48 hrs by qRT-PCR analysis	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1647142	Reduction in CDK2 mRNA level in human HT1080 cells incubated for 48 hrs by qRT-PCR analysis	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668471	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells assessed as fold change in mitoxantrone IC50 at 2 uM after 72 hrs by CCK8 assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668489	Effect on etoposide-induced cytotoxicity against HEK293 cells assessed as fold change in etoposide IC50 at 0.5 uM after 72 hrs by CCK8 assay relative to etoposide IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668498	Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as effect on colchicine-induced cytotoxicity at 3 uM by measuring colchine IC50 after 72 hrs by CCK8 assay (Rvb = 97.58 +/- 17.62 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1244029	Inhibition of Plasmodium falciparum Cytochrome b-c1 complex	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.
AID1453610	Growth inhibition of human LO2 cells at 10 uM after 24 hrs by MTS assay relative to control	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1668487	Effect on etoposide-induced cytotoxicity against HEK293 cells assessed as fold change in etoposide IC50 at 2 uM after 72 hrs by CCK8 assay relative to etoposide IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID519608	Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1272823	Antileishmanial activity against promastigotes of Leishmania major MHOM/IL/67/LRC-L43 assessed as parasite growth inhibition after 24 hrs by uranyl acetate/ magnesium uranyl acetate/lead citrate staining-based electron microscopic analysis	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Antileishmanial activity of novel indolyl-coumarin hybrids: Design, synthesis, biological evaluation, molecular docking study and in silico ADME prediction.
AID1244010	Anti-leishmanial activity against Leishmania donovani infected in hamsters assessed as reduction in parasite load in spleen at 20 mg/kg/day, ip for 6 consecutive days	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.
AID386908	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 13150 after 20 hrs by microdilution assay	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Functionalized chalcones with basic functionalities have antibacterial activity against drug sensitive Staphylococcus aureus.
AID1463931	Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in liver lesions by measuring necrosis at 50 mg/kg, po administered once daily for 7 consecutive days followed by CCL4 challenge 6 hrs after last dose and measu	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668482	Reversal of human ABCC1-mediated multidrug resistance in HEK293/MRP1 cells assessed as effect on etoposide-induced cytotoxicity by measuring etoposide IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 63.34 +/- 7.92 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463944	Apparent clearance during terminal phase in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1484040	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 10 uM after 24 hrs by Griess assay relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1668447	Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 4.83 +/- 0.83 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463919	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells at 2.5 to 10 uM incubated for 6 hrs by ARE-driven luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1463938	Tmax in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID244825	Minimum inhibitory concentration against Enterococcus faecium ATCC 292121	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Cationic chalcone antibiotics. Design, synthesis, and mechanism of action.
AID1668431	Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 9.21 +/- 1.45 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668405	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as fold change in mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668364	Upregulation of ABCG2 mRNA expression in human LS180 cells at 1 uM by Western blot analysis relative to control	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668386	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as fold change in topotecan IC50 at 3 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1604233	Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID1647127	Inhibition of IDH1 R132C mutant (unknown origin) at 30 uM by enzymatic assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668380	Cytotoxicity against human H460 cells after 72 hrs by MTT assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668406	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 1160.60 +/- 365.72 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668479	Reversal of human ABCC1-mediated multidrug resistance in HEK293/MRP1 cells assessed as fold-change in etoposide IC50 at 2 uM after 72 hrs by CCK8 relative to etoposide IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668485	Reversal of human ABCC1-mediated multidrug resistance in HEK293/MRP1 cells assessed as effect on etoposide-induced cytotoxicity by measuring etoposide IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 63.34 +/- 7.92 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647151	Induction of cell cycle arrest in human HT1080 cells assessed accumulation at S phase at 10 uM incubated for 24 hrs by flow cytometric analysis (Rvb = 52.69%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668362	Upregulation of ABCB1 mRNA expression in human LS180 cells at 1 uM by Western blot analysis relative to control	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1244009	Anti-leishmanial activity against Leishmania donovani infected in hamsters assessed as reduction in parasite load in liver at 20 mg/kg/day, ip for 6 consecutive days	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.
AID549519	Noncompetitive inhibition of Influenza A H1N1 virus neuraminidase activity by Lineweaver-Burk plot analysis	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID386910	Toxicity in sheep erythrocytes assessed as hemolysis at 100 uM after 90 mins	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Functionalized chalcones with basic functionalities have antibacterial activity against drug sensitive Staphylococcus aureus.
AID1431556	Lipophilicity, log P of the compound	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.
AID1668430	Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 9.21 +/- 1.45 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668434	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as fold-change in mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID100427	Tested in vitro for anti-leishmanial activity against Leishmania donovani	1998	Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24	Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis.
AID1453625	Inhibition of mushroom tyrosinase at 10 uM using L-tyrosine as substrate incubated for 15 mins followed by substrate addition relative to control	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1668448	Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 4.83 +/- 0.83 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1850405	Antileishmanial activity against Leishmania major assessed as inhibition of parasite growth incubated for 2 hrs by [3H]thymidine incorporation assay	2022	RSC medicinal chemistry, Mar-23, Volume: 13, Issue:3	Identification of 2-arylquinazolines with alkyl-polyamine motifs as potent antileishmanial agents: synthesis and biological evaluation studies.
AID1463932	Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in liver lesions by measuring ballooning degeneration at 50 mg/kg, po administered once daily for 7 consecutive days followed by CCL4 challenge 6 hrs after last	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1244011	Anti-leishmanial activity against Leishmania donovani infected in hamsters assessed as reduction in parasite load in liver at 5 to 150 mg/kg/day, po for 6 consecutive days	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.
AID310825	Inhibition of Leishmania donovani amastigotes in human monocyte-derived macrophages	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1647126	Inhibition of IDH1 (unknown origin) at 30 uM by enzymatic assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668484	Reversal of human ABCC1-mediated multidrug resistance in HEK293/MRP1 cells assessed as effect on etoposide-induced cytotoxicity by measuring etoposide IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 63.34 +/- 7.92 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668509	Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668426	Effect on topotecan-induced cytotoxicity against human S1 cells assessed as fold change in topotecan IC50 at 3 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463939	Half life in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668390	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 1319.20 +/- 356.14 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668511	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as potentiation of mitoxantrone-induced cytotoxicity after 72 hrs by CCK8 assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1272824	Antileishmanial activity against promastigotes of Leishmania donovani assessed as parasite growth inhibition	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Antileishmanial activity of novel indolyl-coumarin hybrids: Design, synthesis, biological evaluation, molecular docking study and in silico ADME prediction.
AID310805	Antibacterial activity against methicillin-sensitive Staphylococcus aureus FDA209P	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID310806	Antibacterial activity against methicillin-sensitive Staphylococcus aureus Smith	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668437	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as fold-change in mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463920	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells at 10 uM incubated for 6 hrs by ARE-driven luciferase reporter gene assay relative to untreated control	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668379	Cytotoxicity against human GES-1 cells	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668360	Induction of apoptosis in human S1 cells assessed as late apoptotic cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 3.6%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668377	Modulation of human ABCC1 expressed in HEK293/MRP1 cells assessed as increase in intracellular calcein-AM accumulation at 20 uM incubated for 10 mins by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1453623	Inhibition of recombinant human PTP1B using p-nitrophenyl phosphate as substrate at 10 uM after 30 mins relative to control	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1647133	Binding affinity to IDH1 R132H mutant (unknown origin) by mass spectrometry	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668371	Induction of pheophorbide A accumulation in human H460 cells at 20 uM incubated for 1 hr by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668472	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells assessed as fold change in mitoxantrone IC50 at 1 uM after 72 hrs by CCK8 assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668397	Effect on topotecan-induced cytotoxicity against human H460 cells assessed as fold change in topotecan IC50 at 0.5 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1484048	Antiproliferative activity against human SW480 cells at 10 uM after 24 hrs by MTS assay relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1668384	Cytotoxicity against human S1 cells after 72 hrs by MTT assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668481	Reversal of human ABCC1-mediated multidrug resistance in HEK293/MRP1 cells assessed as fold-change in etoposide IC50 at 0.5 uM after 72 hrs by CCK8 relative to etoposide IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647135	Inhibition of IDH1 R132C mutant (unknown origin) by enzymatic assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668393	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 1319.20 +/- 356.14 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310868	Antibacterial activity against Mycobacterium bovis	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1604229	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID1647131	Binding affinity to IDH1 R132H mutant (unknown origin) by surface plasmon resonance assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668492	Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463940	AUC (0 to t) in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID310817	Inhibition of Leishmania major NADH dehydrogenase	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1850404	Antileishmanial activity against Leishmania donovani assessed as inhibition of parasite growth incubated for 2 hrs by y [3H]thymidine incorporation assay	2022	RSC medicinal chemistry, Mar-23, Volume: 13, Issue:3	Identification of 2-arylquinazolines with alkyl-polyamine motifs as potent antileishmanial agents: synthesis and biological evaluation studies.
AID1647136	Inhibition of IDH1 R132H mutant (unknown origin) by enzymatic assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1647160	Induction of apoptosis in human HT1080 cells assessed as viable cells at 10 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 95.9%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668349	Induction of apoptosis in human S1-M1-80 cells harboring ABCG2 (unknown origin) assessed as early apoptotic cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 2.8%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1484039	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells at 10 uM after 6 hrs by ARE-driven luciferase reporter gene assay relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1668337	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as fold change in mitoxantrone IC50 at 3 uM after 72 hrs by CCK8 assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647162	Induction of apoptosis in human HT1080 cells assessed as late apoptotic cells at 10 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 2.48%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID310812	Antibacterial activity against Mycobacterium tuberculosis	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1647165	Induction of apoptosis in human HT1080 cells assessed as early apoptotic cells at 20 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 0.63%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID549516	Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1668422	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668382	Cytotoxicity against human S1-M1-80 cells harboring ABCG2 (unknown origin) after 72 hrs by MTT assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310821	Inhibition of Leishmania major NADH-dehydrogenase in human PBMCs crude mitochondria after 60 mins	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1647159	Induction of apoptosis in human HT1080 cells assessed as necrotic cells at 5 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 0.95%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1647168	Induction of cell cycle arrest in human HT1080 cells assessed accumulation at G2 phase incubated for 24 hrs by flow cytometric analysis	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1514102	Antileishmanial activity against Leishmania donovani promastigotes infected in hamster assessed as reduction in parasitic load in liver at 20 mg/kg, ip treated for 6 consecutive days measured at day 8 post last dose by 3H-thymidine incorporation assay rel	2018	European journal of medicinal chemistry, Dec-05, Volume: 160	Leishmania treatment and prevention: Natural and synthesized drugs.
AID1463941	AUC (0 to infinity) in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1244030	Inhibition of Plasmodium falciparum succinate-ubiquinone oxidoreductase	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.
AID1372443	Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 20 mg/kg, po treated with ammonia 1 hr before and 2.5 hrs after test compound dosing measured for 3 mins	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Antitussive and expectorant activities of licorice and its major compounds.
AID1604235	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID1453609	Growth inhibition of human HEK293T cells at 10 uM after 24 hrs by MTS assay relative to control	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1484069	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 6 hrs by ARE-driven luciferase reporter gene assay relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1668428	Effect on topotecan-induced cytotoxicity against human S1 cells assessed as fold change in topotecan IC50 at 1 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID312864	Inhibition of fumarate reductase in crude mitochondria fraction of Leishmania major promastigotes	2008	Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3	2-(3-aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial chemotype.
AID310804	Antibacterial activity against methicillin-resistant Staphylococcus aureus ST28	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID310803	Antibacterial activity against methicillin-resistant Staphylococcus aureus K3	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668429	Effect on topotecan-induced cytotoxicity against human S1 cells assessed as fold change in topotecan IC50 at 0.5 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1484068	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS induced nitric oxide production at 20 uM preincubated for 24 hrs followed by LPS challenge measured after 15 mins relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1668346	Potentiation of topotecan-induced apoptosis in human S1-M1-80 cells harboring ABCG2 (unknown origin) assessed as viable cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 90.6%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647163	Induction of apoptosis in human HT1080 cells assessed as necrotic cells at 10 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 0.95%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668376	Modulation of human ABCG2 expressed in HEK293/R482 cells assessed as increase in intracellular pheophorbide A accumulation at 20 uM incubated for 1 hr by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668420	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as fold-change in topotecan IC50 at 1 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463933	Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in liver lesions by measuring neutrophil infiltration at 50 mg/kg, po administered once daily for 7 consecutive days followed by CCL4 challenge 6 hrs after last	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668383	Cytotoxicity against HEK293 cells after 72 hrs by CCK8 assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668466	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 50.66 +/- 6.88 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1453619	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM after 24 hrs by Griess reagent based assay relative to control	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1244012	Anti-leishmanial activity against Leishmania donovani infected in hamsters assessed as reduction in parasite load in spleen at 5 to 150 mg/kg/day, po for 6 consecutive days	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.
AID1453615	Growth inhibition of human SW480 cells at 10 uM after 24 hrs by MTS assay relative to control	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1463946	VRT (0 to t) in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID310819	Inhibition of Leishmania major NADH-cytochrome c reductase	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1647149	Induction of cell cycle arrest in human HT1080 cells assessed accumulation at G2 phase at 5 uM incubated for 24 hrs by flow cytometric analysis (Rvb = 15.64%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668421	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as fold-change in topotecan IC50 at 0.5 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1453622	Inhibition of LPS-induced NF-kappaB transcription (unknown origin) expressed in human SW480 cells by luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1488475	Inhibition of recombinant human ACE at 100 uM using Mca-R-P-PG-F-S-A-F-K(Dnp)-OH as substrate measured every 2 mins for 8 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Discovery of a potent angiotensin converting enzyme inhibitor via virtual screening.
AID1668348	Induction of apoptosis in human S1-M1-80 cells harboring ABCG2 (unknown origin) assessed as late apoptotic cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 2.9%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310832	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1667214	Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 25 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1604237	Cytotoxicity against human NCI-H28 cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID1647167	Induction of apoptosis in human HT1080 cells assessed as necrotic cells at 20 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 0.95%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668490	Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668450	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as fold-change in topotecan IC50 at 3 uM after 72 hrs by CCK8 relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668444	Effect on mitoxantrone-induced cytotoxicity against human S1 cells assessed as fold change in mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668417	Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310818	Inhibition of Leishmania major succinate-cytochrome c reductase	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1463929	Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as aspartate aminotransferase level at 50 mg/kg, po administered once daily for 7 consecutive days followed by CCL4 challenge 6 hrs after last dose and measured 24 hrs post	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668461	Effect on topotecan-induced cytotoxicity against HEK293 cells assessed as fold change in topotecan IC50 at 0.5 uM after 72 hrs by CCK8 assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668395	Effect on topotecan-induced cytotoxicity against human H460 cells assessed as fold change in topotecan IC50 at 2 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668443	Effect on mitoxantrone-induced cytotoxicity against human S1 cells assessed as fold change in mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1484037	Inhibition of recombinant human PTP1B using pNPP as substrate at 10 uM after 30 mins relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1647130	Binding affinity to IDH1 R132C mutant (unknown origin) by surface plasmon resonance assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668402	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as fold change in mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668499	Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as effect on colchicine-induced cytotoxicity at 2 uM by measuring colchine IC50 after 72 hrs by CCK8 assay (Rvb = 97.58 +/- 17.62 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1604236	Cytotoxicity against human MSTO-211H cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID1668361	Induction of apoptosis in human S1 cells assessed as early apoptotic cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 2%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668462	Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463930	Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as LDH level at 50 mg/kg, po administered once daily for 7 consecutive days followed by CCL4 challenge 6 hrs after last dose and measured 24 hrs post CCL4 injection (Rvb = 2	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668418	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as fold-change in topotecan IC50 at 3 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1484034	Inhibition of tyrosinase (unknown origin) using L-tyrosine as substrate at 10 uM preincubated for 15 mins followed by substrate addition relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1514099	Antileishmanial activity against Leishmania donovani MHOM/SD/00/1SD2D axenic amastigotes infected in human peripheral blood mononuclear cells after 3 days by 3H-thymidine incorporation assay	2018	European journal of medicinal chemistry, Dec-05, Volume: 160	Leishmania treatment and prevention: Natural and synthesized drugs.
AID310814	Antibacterial activity against Mycobacterium marinum	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668455	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 201.31 +/- 25.89 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647145	Reduction in ACO1 protein expression in human HT1080 cells by RNA-Seq data analysis	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1372434	Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 50 mg/kg, po treated with ammonia 1 hr before and 2.5 hrs after test compound dosing measured for 3 mins relative to control	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Antitussive and expectorant activities of licorice and its major compounds.
AID1668433	Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 9.21 +/- 1.45 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310794	Antibacterial activity against Staphylococcus aureus	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668411	Effect on mitoxantrone-induced cytotoxicity against human H460 cells assessed as fold change in mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668505	Effect on Colchicine-induced cytotoxicity against HEK293 cells assessed as fold change in colchicine IC50 at 0.5 uM after 72 hrs by CCK8 assay relative to colchicine IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668370	Induction of pheophorbide A accumulation in human S1 cells at 20 uM incubated for 1 hr by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668442	Effect on mitoxantrone-induced cytotoxicity against human S1 cells assessed as fold change in mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1372433	Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 50 mg/kg, po treated with ammonia 1 hr before and 1 hr after test compound dosing measured for 3 mins relative to control	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Antitussive and expectorant activities of licorice and its major compounds.
AID1647146	Reduction in PDHB protein expression in human HT1080 cells by RNA-Seq data analysis	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668375	Modulation of ABCG2 (unknown origin) expressed in S1-M1-80 cells assessed as increase in intracellular pheophorbide A accumulation at 20 uM incubated for 1 hr by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668503	Effect on Colchicine-induced cytotoxicity against HEK293 cells assessed as fold change in colchicine IC50 at 3 uM after 72 hrs by CCK8 assay relative to colchicine IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668350	Induction of apoptosis in human S1-M1-80 cells harboring ABCG2 (unknown origin) assessed as viable cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 93.9%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647132	Binding affinity to IDH1 R132C mutant (unknown origin) by mass spectrometry	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID310790	Antibacterial activity against Bacillus subtilis	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1647150	Induction of cell cycle arrest in human HT1080 cells assessed accumulation at G1 phase at 10 uM incubated for 24 hrs by flow cytometric analysis (Rvb = 31.67%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID549515	Inhibition of Influenza A H1N1 virus neuraminidase activity after 2 hrs by spectrofluorometry	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1463928	Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as alanine aminotransferase level at 50 mg/kg, po administered once daily for 7 consecutive days followed by CCL4 challenge 6 hrs after last dose and measured 24 hrs post CC	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668359	Induction of apoptosis in human S1 cells assessed as necrotic cells at 10 uM incubated for 48 hrs by annexin V/propidium iodide staining based flow cytometry (Rvb = 0.2%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1484045	Antiproliferative activity against human HepG2 cells at 10 uM after 24 hrs by MTS assay relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID1668419	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as fold-change in topotecan IC50 at 2 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647134	Inhibition of IDH1 (unknown origin) by enzymatic assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668451	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as fold-change in topotecan IC50 at 2 uM after 72 hrs by CCK8 relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668486	Effect on etoposide-induced cytotoxicity against HEK293 cells assessed as fold change in etoposide IC50 at 3 uM after 72 hrs by CCK8 assay relative to etoposide IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647158	Induction of apoptosis in human HT1080 cells assessed as late apoptotic cells at 5 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 2.48%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID310869	Antibacterial activity against Mycobacterium xenopi	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1604321	Antiparasitic activity against Toxoplasma gondii	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening.
AID1668369	Inhibition of human ABCG2-mediated pheophorbide A efflux in HEK293/R482 cells incubated for 1 hr by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668352	Induction of apoptosis in human S1 cells assessed as late apoptotic cells at 10 uM incubated for 48 hrs in presence of topotecan by annexin V/propidium iodide staining based flow cytometry (Rvb = 3.6%)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1516838	Antifungal activity against Trichophyton rubrum	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Recent advances in natural antifungal flavonoids and their derivatives.
AID310799	Antibacterial activity against Staphylococcus mutans	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID245195	Minimum inhibitory concentration against Enterococcus faecium 17501 (vancomycin-resistant clinical isolate)	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Cationic chalcone antibiotics. Design, synthesis, and mechanism of action.
AID90472	Inhibitory activity against phytohemagglutininin A-induced proliferation of human lymphocytes	1998	Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24	Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis.
AID310820	Inhibition of Leishmania major succinate dehydrogenase in human PBMCs crude mitochondria after 60 mins	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1875274	Inhibition of MMP1 in human U2OS cells at 5 umol/L by peptide microarray-based fluorescence assay	2022	Journal of natural products, 10-28, Volume: 85, Issue:10	Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID1647138	Cytotoxicity against human RCTEC incubated for 48 hrs	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1647152	Induction of cell cycle arrest in human HT1080 cells assessed accumulation at G2 phase at 10 uM incubated for 24 hrs by flow cytometric analysis (Rvb = 15.64%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668496	Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as fold change in colchicine IC50 at 1 uM after 72 hrs by CCK8 relative to colchicine IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668491	Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID538331	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human O+ erythrocytes after 72 hrs by SYBR Green-1 fluorescence based assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Reinvestigation of structure-activity relationship of methoxylated chalcones as antimalarials: synthesis and evaluation of 2,4,5-trimethoxy substituted patterns as lead candidates derived from abundantly available natural β-asarone.
AID1668341	Modulation of ABCG2 (unknown origin) expressed in High Five insect cell vesicle membrane assessed as maximal stimulation of ATPase activity after 20 mins by colorimetric assay relative to baseline	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668460	Effect on topotecan-induced cytotoxicity against HEK293 cells assessed as fold change in topotecan IC50 at 1 uM after 72 hrs by CCK8 assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647154	Induction of cell cycle arrest in human HT1080 cells assessed accumulation at S phase at 20 uM incubated for 24 hrs by flow cytometric analysis (Rvb = 52.69%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1514100	Antileishmanial activity against Leishmania major MHOM/IL/67/LRC-L137 promastigotes after 2 hrs by 3H-thymidine incorporation assay	2018	European journal of medicinal chemistry, Dec-05, Volume: 160	Leishmania treatment and prevention: Natural and synthesized drugs.
AID1463937	Cmax in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668483	Reversal of human ABCC1-mediated multidrug resistance in HEK293/MRP1 cells assessed as effect on etoposide-induced cytotoxicity by measuring etoposide IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 63.34 +/- 7.92 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668389	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as fold change in topotecan IC50 at 0.5 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668458	Effect on topotecan-induced cytotoxicity against HEK293 cells assessed as fold change in topotecan IC50 at 3 uM after 72 hrs by CCK8 assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668399	Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID519606	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1647156	Induction of apoptosis in human HT1080 cells assessed as viable cells at 5 uM incubated for 48 hrs by flow cytometric analysis (Rvb = 95.9%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668476	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1624911	Inhibition of recombinant human PTP1B using pNPP as substrate measured after 30 mins	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis, biological evaluation, and molecular docking study of novel allyl-retrochalcones as a new class of protein tyrosine phosphatase 1B inhibitors.
AID1668438	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668457	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 201.31 +/- 25.89 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668391	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 1319.20 +/- 356.14 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668469	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells assessed as fold change in mitoxantrone IC50 at 3 uM after 72 hrs by CCK8 assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID310801	Antibacterial activity against methicillin-resistant Staphylococcus aureus OM481	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668374	Modulation of ABCG2 (unknown origin) expressed in H460-MX20 cells assessed as increase in intracellular pheophorbide A accumulation at 20 uM incubated for 1 hr by FACScan flow cytometry	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID386911	Toxicity in sheep erythrocytes assessed as hemolysis at 25 uM after 90 mins	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Functionalized chalcones with basic functionalities have antibacterial activity against drug sensitive Staphylococcus aureus.
AID1604232	Cytotoxicity against human HK2 cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins.
AID1668416	Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID683699	Antimalarial activity against liver stages of Plasmodium yoelii yoelii	2012	Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3	Targeting the liver stage of malaria parasites: a yet unmet goal.
AID1668449	Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 4.83 +/- 0.83 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1484047	Antiproliferative activity against human MCF7 cells at 10 uM after 24 hrs by MTS assay relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
AID386912	Toxicity in sheep erythrocytes assessed as hemolysis at 300 uM after 90 mins	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Functionalized chalcones with basic functionalities have antibacterial activity against drug sensitive Staphylococcus aureus.
AID310813	Antibacterial activity against Mycobacterium kansasii	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	A review of anti-infective and anti-inflammatory chalcones.
AID1668338	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as fold change in mitoxantrone IC50 at 2 uM after 72 hrs by CCK8 assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668497	Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as fold change in colchicine IC50 at 0.5 uM after 72 hrs by CCK8 relative to colchicine IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668339	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as fold change in mitoxantrone IC50 at 1 uM after 72 hrs by CCK8 assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID436204	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in type B+ human erythrocytes assessed as inhibition of parasitemia after 48 hrs by Giemsa staining	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Antimalarial pharmacodynamics of chalcone derivatives in combination with artemisinin against Plasmodium falciparum in vitro.
AID1668409	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 1160.60 +/- 365.72 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668424	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1647155	Induction of cell cycle arrest in human HT1080 cells assessed accumulation at G2 phase at 20 uM incubated for 24 hrs by flow cytometric analysis (Rvb = 15.64%)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
AID1668427	Effect on topotecan-induced cytotoxicity against human S1 cells assessed as fold change in topotecan IC50 at 2 uM after 72 hrs by MTT assay relative to topotecan IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668504	Effect on Colchicine-induced cytotoxicity against HEK293 cells assessed as fold change in colchicine IC50 at 1 uM after 72 hrs by CCK8 assay relative to colchicine IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1668404	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human H460-MX20 cells assessed as fold change in mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay relative to mitoxantrone IC50	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
AID1463943	MRT (0 to infinity) in Sprague-Dawley rat at 50 mg/kg, po administered as single dose measured after 0.08 to 24 hrs post dose by LC/MS/MS method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1668467	Reversal of human ABCG2-mediated multidrug resistance in HEK293/R482 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 50.66 +/- 6.88 nM)	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	12 (5.02)	18.2507
2000's	37 (15.48)	29.6817
2010's	131 (54.81)	24.3611
2020's	59 (24.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	10 (4.10%)	5.53%
Reviews	15 (6.15%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	219 (89.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.11	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	2.45	2	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
aminooxyacetic acid Aminooxyacetic Acid: A compound that inhibits aminobutyrate aminotransferase activity in vivo, thereby raising the level of gamma-aminobutyric acid in tissues.. (aminooxy)acetic acid : A member of the class of hydroxylamines that is acetic acid substituted at postion 2 by an aminooxy group. It is a compound which inhibits aminobutyrate aminotransferase activity in vivo, resulting in increased levels of gamma-aminobutyric acid in tissues.	2.05	1	0	amino acid; hydroxylamines; monocarboxylic acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor; EC 4.2.1.22 (cystathionine beta-synthase) inhibitor; nootropic agent
carnitine [no description available]	4.82	3	2	amino-acid betaine	human metabolite; mouse metabolite
methane Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed). methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).	2.6	1	0	alkane; gas molecular entity; mononuclear parent hydride; one-carbon compound	bacterial metabolite; fossil fuel; greenhouse gas
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	7.41	1	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	2.05	1	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	3.47	1	1	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	3.47	1	1	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
vanillin Vanilla: A plant genus of the family ORCHIDACEAE that is the source of the familiar flavoring used in foods and medicines (FLAVORING AGENTS).	2.15	1	0	benzaldehydes; monomethoxybenzene; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; flavouring agent; plant metabolite
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.31	1	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
4-phenyl-3-furoxancarbonitrile 4-phenyl-3-furoxancarbonitrile: structure given in first source. 4-phenyl-3-furoxancarbonitrile : A 1,2,5-oxadiazole substituted by an oxido, cyano and phenyl groups at positions 2, 3 and 4, respectively. It is a vasodilator and inhibitor of platelet aggregation.	3.35	1	0	1,2,5-oxadiazole; benzenes; N-oxide; nitrile	geroprotector; nitric oxide donor; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
phenytoin [no description available]	2.05	1	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
acebutolol Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.	2.05	1	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.05	1	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	2.05	1	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohydroxamic acid acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.	2.05	1	0	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	2.05	1	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	2.05	1	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	2.05	1	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.05	1	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
theophylline [no description available]	2.05	1	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.05	1	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
dan 2163 [no description available]	2.25	1	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	2.05	1	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	2.05	1	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
aprindine Aprindine: A class Ib anti-arrhythmia agent used to manage ventricular and supraventricular arrhythmias.	2.05	1	0	indanes
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	2.05	1	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	2.05	1	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	2.05	1	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
bepridil Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.	2.05	1	0	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	2.05	1	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bretylium bretylium: RN given refers to parent cpd. bretylium : A quaternary ammonium cation having 2-bromobenzyl, ethyl and two methyl groups attached to the nitrogen. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.	2.05	1	0	quaternary ammonium ion	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent
bromhexine Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).	2.05	1	0	organobromine compound; substituted aniline; tertiary amino compound	mucolytic
bumetanide [no description available]	2.05	1	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.05	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	2.05	1	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.05	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carteolol Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.	2.05	1	0	quinolone; secondary alcohol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
cgs 15943 9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine: non-xanthine triazoloquinazoline adenosine antagonist. CGS 15943 : A member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors.	3.35	1	0	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant
chlordiazepoxide Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.	2.05	1	0	benzodiazepine
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.94	4	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.05	1	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	2.05	1	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.	2.05	1	0	isoindoles; monochlorobenzenes; sulfonamide
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	2.05	1	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.02	1	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	2.05	1	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
cl 387785 CL 387785: structure in first source. N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.	3.35	1	0	bromobenzenes; quinazolines; secondary carboxamide; ynamide	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
clenbuterol Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.. clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.05	1	0	amino alcohol; dichlorobenzene; ethanolamines; primary arylamine; secondary amino compound; substituted aniline	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	2.05	1	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	2.05	1	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	2.05	1	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	2.05	1	0	clonidine; imidazoline
chlorazepate clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.	2.05	1	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
dapsone [no description available]	2.05	1	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
debrisoquin Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.	2.05	1	0	carboxamidine; isoquinolines	adrenergic agent; antihypertensive agent; human metabolite; sympatholytic agent
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	3.17	1	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	2.05	1	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.05	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	2.05	1	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	2.05	1	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
3,4-dihydroxybenzohydroxamic acid [no description available]	2.05	1	0	benzoic acids
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	2.05	1	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
dimercaprol Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.	2.05	1	0	dithiol; primary alcohol	chelator
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.05	1	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	2.1	1	0
ethacrynic acid Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.	2.05	1	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
ethosuximide Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.	2.05	1	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
ethyl loflazepate ethyl loflazepate: structure given in first source	2.05	1	0	organic molecular entity
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	2.05	1	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenbendazole Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.. fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.	2.04	1	0	aryl sulfide; benzimidazoles; carbamate ester	antinematodal drug
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.05	1	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.05	1	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	2.05	1	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	3.31	1	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
fluphenazine [no description available]	2.05	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.05	1	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	2.05	1	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	2.05	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.46	2	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
glutethimide Glutethimide: A hypnotic and sedative. Its use has been largely superseded by other drugs.	2.05	1	0	piperidines
guaifenesin Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.	2.17	1	0	methoxybenzenes
guanethidine Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.	2.05	1	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
hexachlorophene Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.	3.17	1	0	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	4	3	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	2.05	1	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroxyurea [no description available]	2.05	1	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	3.61	2	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.05	1	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
phenelzine Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.	2.05	1	0	primary amine
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.05	1	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.05	1	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	2.05	1	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
incadronate [no description available]	2.05	1	0	1,1-bis(phosphonic acid)
indapamide Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.	2.05	1	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.49	2	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
1-methyl-3-isobutylxanthine 1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.	2.03	1	0	3-isobutyl-1-methylxanthine
nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).	2.05	1	0	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.05	1	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.05	1	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.05	1	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.05	1	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketotifen Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.	2.05	1	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	2.05	1	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	2.05	1	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
lapachol lapachol : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae.	2.25	1	0
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.25	1	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
lofepramine Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.	2.05	1	0	aromatic ketone; dibenzoazepine; monochlorobenzenes; tertiary amino compound	antidepressant
lomefloxacin lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.	2.25	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antimicrobial agent; antitubercular agent; photosensitizing agent
lomustine [no description available]	2.05	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
lorazepam Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.	2.05	1	0	benzodiazepine
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	2.08	1	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
maprotiline Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.	2.05	1	0	anthracenes
mazindol Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.	2.05	1	0	organic molecular entity
mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.	2.05	1	0	nitrogen mustard; organochlorine compound	alkylating agent
mefloquine hydrochloride [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.	2.05	1	0	organofluorine compound; piperidines; quinolines; secondary alcohol
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	2.05	1	0	imidazolidine-2,4-dione	anticonvulsant
methoxyamine methoxyamine: analytical reagent for aldehydes and ketones; strong irritant, can probably produce methemoglobinemia; RN given refers to parent cpd; structure	2.05	1	0	organooxygen compound
methoxyflurane Methoxyflurane: An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with NITROUS OXIDE to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180). methoxyflurane : An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl.	2.05	1	0	ether; organochlorine compound; organofluorine compound	hepatotoxic agent; inhalation anaesthetic; nephrotoxic agent; non-narcotic analgesic
methylphenidate Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.	2.05	1	0	beta-amino acid ester; methyl ester; piperidines
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	2.05	1	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	3.83	2	1	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	2.05	1	0	aromatic ether; primary amino compound	anti-arrhythmia drug
mianserin Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.	2.05	1	0	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.04	1	0	dichlorobenzene; ether; imidazoles
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	2.05	1	0	dialkylarylamine; tertiary amino compound
nabumetone Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.	2.05	1	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	3.31	1	0	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	7.48	2	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.05	1	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	2.05	1	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	2.05	1	0	isoquinolines	dopamine uptake inhibitor
masoprocol nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)	2.04	1	0	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	2.05	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	2.05	1	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.05	1	0	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	2.05	1	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
oxamniquine Oxamniquine: An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martindale, The Extra Pharmacopoeia, 31st ed, p121). oxamniquine : A racemate comprising equimolar amounts of (R)- and (S)-oxamniquine. An anthelmintic, it is administered orally for the treatment of schistomiasis caused by Schistosoma mansoni (but not by other Schistosoma species); intramuscular administration is no longer used as it causes severe pain at the injection site.. {2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol : A member of the class of quinolines that is 1,2,3,4-tetrahydroquinoline which is substituted at positions 2, 6, and 7 by (isopropylamino)methyl, hydroxymethyl, and nitro groups, respectively.	3.35	1	0	aromatic primary alcohol; C-nitro compound; quinolines; secondary amino compound
oxatomide oxatomide: structure; an anti-allergic & an anti-asthmatic. oxatomide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug.	2.05	1	0	benzimidazoles; diarylmethane; N-alkylpiperazine	anti-allergic agent; anti-inflammatory agent; geroprotector; H1-receptor antagonist; serotonergic antagonist
oxazepam Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.	2.05	1	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
oxprenolol Oxprenolol: A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.	2.05	1	0	aromatic ether
oxyphenbutazone Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.	2.05	1	0	phenols; pyrazolidines	antimicrobial agent; antineoplastic agent; antipyretic; drug metabolite; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic metabolite
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	2.05	1	0	aminobenzoic acid; phenols	antitubercular agent
pamidronate [no description available]	2.05	1	0	phosphonoacetic acid
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	2.05	1	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	2.05	1	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.1	1	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.79	3	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	2.05	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.05	1	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenindione Phenindione: An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)	2.05	1	0	aromatic ketone; beta-diketone	anticoagulant
phentermine Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.	2.05	1	0	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.	2.05	1	0	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
phloretin [no description available]	3.13	1	0	dihydrochalcones	antineoplastic agent; plant metabolite
praziquantel azinox: Russian drug	3.35	1	0	isoquinolines
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	3.85	3	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	2.05	1	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
procaine Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).. procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.	2.05	1	0	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
procarbazine Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	2.05	1	0	benzamides; hydrazines	antineoplastic agent
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	2.05	1	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.05	1	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
pyrimethamine Maloprim: contains above 2 cpds	3.85	3	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rabeprazole Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.	2.05	1	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
ranitidine [no description available]	2.05	1	0	aralkylamine
rimantadine Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	3.56	2	0	alkylamine
sulfadiazine Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.	2.17	1	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	2.05	1	0	pyridines
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.31	1	0
sulforaphane sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.	2.05	1	0	isothiocyanate; sulfoxide	antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite
terbutaline Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.05	1	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.05	1	0	diarylmethane
thioridazine Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.	2.05	1	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	2.05	1	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	2.05	1	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	2.05	1	0	pteridines	diuretic; sodium channel blocker
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	2.05	1	0	triazolobenzodiazepine	sedative
trifluoperazine [no description available]	2.05	1	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trimethadione Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.	2.05	1	0	oxazolidinone	anticonvulsant; geroprotector
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.05	1	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	3.56	2	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.	2.07	1	0	aromatic primary alcohol; furans; indazoles	antineoplastic agent; apoptosis inducer; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
zopiclone zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.	2.05	1	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.05	1	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
paramethasone Paramethasone: A glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than HYDROCORTISONE with supplementary FLUDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p737)	2.05	1	0	fluorinated steroid
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2.04	1	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	7.05	1	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cetrimonium bromide cetyltrimethylammonium bromide : The organic bromide salt that is the bromide salt of cetyltrimethylammonium; one of the components of the topical antiseptic cetrimide.	2.05	1	0	organic bromide salt; quaternary ammonium salt	detergent; surfactant
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.05	1	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.05	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
fluocinolone acetonide Fluocinolone Acetonide: A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluocinolone acetonide : A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders.	2.05	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; glucocorticoid; organic heteropentacyclic compound; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
mannitol [no description available]	2.05	1	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine [no description available]	2.05	1	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
sulfobromophthalein sodium bromosulfophthalein sodium : An organic sodium salt that is the disodium salt of bromosulfophthalein.. bromosulfophthalein : An organosulfonic acid that consists of phthalide bearing four bromo substituents at positions 4, 5, 6 and 7 as well as two 4-hydroxy-3-sulfophenyl groups both located at position 1.	2.05	1	0	organic sodium salt	dye
tert-butylhydroperoxide tert-Butylhydroperoxide: A direct-acting oxidative stress-inducing agent used to examine the effects of oxidant stress on Ca(2+)-dependent signal transduction in vascular endothelial cells. It is also used as a catalyst in polymerization reactions and to introduce peroxy groups into organic molecules.. tert-butyl hydroperoxide : An alkyl hydroperoxide in which the alkyl group is tert-butyl. It is widely used in a variety of oxidation processes.	2.11	1	0	alkyl hydroperoxide	antibacterial agent; oxidising agent
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	8.56	1	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.05	1	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
pseudoephedrine Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.	2.05	1	0	phenylethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; bronchodilator agent; central nervous system drug; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.11	1	0	xanthene
thianthrene thianthrene: in its electron deficient state, effects formation of high-energy phosphate bonds in process of oxidative phosphorylation; structure. thianthrene : The organosulfur heterocyclic compound that is the parent compound of the thianthrenes, a tricyclic structure comprising two benzene rings fused to the b and e sides of 1,4-dithin.	3.27	1	0	mancude organic heterotricyclic parent; organosulfur heterocyclic compound; thianthrenes
benzoyl peroxide Benzoyl Peroxide: A peroxide derivative that has been used topically for BURNS and as a dermatologic agent in the treatment of ACNE and POISON IVY DERMATITIS. It is used also as a bleach in the food industry.	2.41	1	0	carbonyl compound
trans-4-tert-butylcyclohexanol 4-tert-butylcyclohexanol: a TRPV1 channel antagonist for treating sensitive skin; structure in first source	5	4	2
cyclohexanol Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.	5	4	2	cyclohexanols; secondary alcohol	solvent
phenformin Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.	2.05	1	0	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent
sterogenol hexadecylpyridinium bromide: structure in first source. cetylpyridinium bromide : A pyridinium salt that has N-hexadecylpyridinium as the cation and bromide as the anion.	2.05	1	0	bromide salt; pyridinium salt	antiseptic drug; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; surfactant
cycloguanil cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source. cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil.	2.05	1	0	triazines	antifolate; antiinfective agent; antimalarial; antiparasitic agent; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	3.68	2	0	catechin	antioxidant; plant metabolite
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2.07	1	0	indazole
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	2.05	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
dextropropoxyphene Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.	2.05	1	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
glycyrrhetinic acid [no description available]	2.17	1	0	cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid	immunomodulator; plant metabolite
aloe emodin aloe emodin: structure distinct from emodin; this does not mean emodin from aloe. Aloe emodin : A dihydroxyanthraquinone that is chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe.	2.31	1	0	aromatic primary alcohol; dihydroxyanthraquinone	antineoplastic agent; plant metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.05	1	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
osthol osthol: from Cnidium monnieri and Angelica pubescens (both Apiaceae); structure given in first source	2.08	1	0	botanical anti-fungal agent; coumarins	metabolite
kainic acid Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.	7.17	1	0	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
benzohydroxamic acid [no description available]	2.05	1	0
oleanolic acid [no description available]	3.31	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
medroxyprogesterone [no description available]	2.05	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
flavone flavone: RN given refers to unlabeled cpd; structure given in first source. flavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2.	3.31	1	0	flavones	metabolite; nematicide
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.21	1	0	dialdehyde	biomarker
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	3.31	1	0	flavonols; monohydroxyflavone
megestrol acetate [no description available]	2.05	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	1.99	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.05	1	0	cyclic ketone; erythromycin
vinblastine [no description available]	3.56	2	0
antimycin a [no description available]	2.41	1	0	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide
glycyrrhizic acid glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.	9.57	7	0	enone; glucosiduronic acid; pentacyclic triterpenoid; tricarboxylic acid; triterpenoid saponin	EC 3.4.21.5 (thrombin) inhibitor; plant metabolite
3-methoxyphenylacetic acid 3-methoxyphenylacetic acid: RN given refers to parent cpd	2	1	0	monocarboxylic acid
paraquat Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.	2.21	1	0	organic cation	geroprotector; herbicide
2-tert-butylhydroquinone 2-tert-butylhydroquinone: an anticarcinogenic and chemopreventive agent. 2-tert-butylhydroquinone : A member of the class of hydroquinones in which one of the ring hydrogens of hydroquinone is replaced by a tert-butyl group.	2.15	1	0	hydroquinones	food antioxidant
sulfadoxine Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.	2.05	1	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
acetophenazine acetophenazine: major descriptor (73-85); minor descriptor (64-72); on-line search PHENOTHIAZINES (64-85); Index Medicus search PHENOTHIAZINES (64-72); ACETOPHENAZINE (73-85); RN given refers to parent cpd. acetophenazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the nitogen atom and an acetyl group at position 2.	2.05	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; phenothiazines	phenothiazine antipsychotic drug
streptomycin [no description available]	2.08	1	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
beclomethasone [no description available]	2.05	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug
pyrodifenium bromide pyrodifenium bromide: was heading 1976-94 (see under PYRROLIDINES 1976-90); PRIFINIUM BROMIDE was see PYRODIFENIUM BROMIDE 1976-94: use PYRROLIDINES to search PYRODIFENIUM BROMIDE 1976-94; quaternary ammonium anticholinergic agent more specific for the gastrointestinal tract than atropine	2.05	1	0	organic molecular entity
galactosamine 2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.	7.21	1	0	D-galactosamine; primary amino compound	toxin
bromine Bromine: A halogen with the atomic symbol Br, atomic number 35, and atomic weight 79.904. It is a volatile reddish-brown liquid that gives off suffocating vapors, is corrosive to the skin, and may cause severe gastroenteritis if ingested.	2.06	1	0	diatomic bromine
amopyroquine amopyroquine: RN given refers to parent cpd; structure	2.05	1	0
xipamide Xipamide: A sulfamoylbenzamide analog of CLOPAMIDE. It is diuretic and saluretic with antihypertensive activity. It is bound to PLASMA PROTEINS, thus has a delayed onset and prolonged action.	2.05	1	0	benzamides
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.05	1	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.01	1	0	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	2.05	1	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
decoquinate Decoquinate: A coccidiostat for poultry.	3.17	1	0
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	2.05	1	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
pedalitin pedalitin: has antioxidant activity; isolated from Rabdosia japonica; structure in first source. pedalitin : A tetrahydroxy-monohydroxy-flavone, with the four hydroxy groups at C-3',-4',-5 and 6, and the methoxy group at C-7. It has been isolated from a number of plant species, including Eremosparton songoricum, Rabdosia japonica and Ruellia tuberosa.	3.31	1	0	monomethoxyflavone; tetrahydroxyflavone	EC 1.17.3.2 (xanthine oxidase) inhibitor; metabolite
triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.	2.05	1	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
chloroprene Chloroprene: Toxic, possibly carcinogenic, monomer of neoprene, a synthetic rubber; causes damage to skin, lungs, CNS, kidneys, liver, blood cells and fetuses. Synonym: 2-chlorobutadiene.	2.02	1	0	chloroolefin
butylated hydroxytoluene 2,6-di-tert-butyl-4-methylphenol : A member of the class of phenols that is 4-methylphenol substituted by tert-butyl groups at positions 2 and 6.	2.13	1	0	phenols	antioxidant; ferroptosis inhibitor; food additive; geroprotector
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2.05	1	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
halazepam halazepam: structure	2.05	1	0	organic molecular entity
dexchlorpheniramine dexchlorpheniramine: RN given refers to parent cpd(S)-isomer	2.05	1	0	chlorphenamine
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	2.05	1	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
nigericin Nigericin: A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed). nigericin : A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus.	2.04	1	0	polycyclic ether	antibacterial agent; antimicrobial agent; bacterial metabolite; potassium ionophore
amineptin amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.	2.05	1	0	amino acid; carbocyclic fatty acid; carbotricyclic compound; secondary amino compound	antidepressant; dopamine uptake inhibitor
etoposide [no description available]	2.49	2	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
dobutamine Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.	3.56	2	0	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
1,10-decanediol [no description available]	3.64	1	1
halofantrine halofantrine: used in treatment of mild to moderate acute malaria	2.05	1	0	phenanthrenes
hydroxymaprotilin hydroxymaprotilin: RN given refers to cpd without isomeric designation	2.05	1	0
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	2.05	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
tocainide Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.	2.05	1	0	monocarboxylic acid amide	anti-arrhythmia drug; local anaesthetic; sodium channel blocker
sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.	2.05	1	0
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	2.05	1	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
pinazepam pinazepam: structure	2.05	1	0	benzodiazepine
butibufen butibufen: RN given refers to parent cpd	2.05	1	0	monoterpenoid
sitamaquine [no description available]	3.17	1	0
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	2.05	1	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	2.49	2	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
staurosporine [no description available]	2.05	1	0	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
alfentanil Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.	2.05	1	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
piritrexim piritrexim: RN given refers to parent cpd; structure given in first source	2.05	1	0
bambuterol bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.	2.05	1	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
salmeterol xinafoate Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.	2.05	1	0	naphthoic acid
adapalene Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.	6.2	3	2	adamantanes; monocarboxylic acid; naphthoic acid	dermatologic drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; non-steroidal anti-inflammatory drug
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	3.56	2	0	tetralins	T-type calcium channel blocker
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	2.25	1	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
irinotecan [no description available]	2.15	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	2.05	1	0
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	2.05	1	0
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	3.41	1	1	D-glucopyranose	epitope; mouse metabolite
ursolic acid [no description available]	4.59	7	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
propamidine propamidine: structure given in first source. propamidine : A polyether that is the bis(4-guanidinophenyl) ether of propane-1,3-diol. Used (as its isethionate salt) for the treatment of minor eye or eyelid infections, such as conjunctivitis and blepharitis.	2.05	1	0	aromatic ether; guanidines; polyether	antimicrobial agent; antiseptic drug
betulinic acid [no description available]	1.99	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
baicalin [no description available]	3.31	1	0	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	2.06	1	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
allicin [no description available]	3.17	1	0	botanical anti-fungal agent; sulfoxide	antibacterial agent
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.68	2	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
lissamine rhodamine b lissamine rhodamine B: RN given refers to parent cpd; Lissamine Rhodamine B refers to Na salt	2.1	1	0
proadifen hydrochloride [no description available]	2.25	1	0
sinefungin [no description available]	2.05	1	0	adenosines; non-proteinogenic alpha-amino acid	antifungal agent; antimicrobial agent
droxicam droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.	2.05	1	0	organic heterotricyclic compound; pyridines	cyclooxygenase 1 inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; prodrug
etofibrate etofibrate: analog of clofibrate with nicotinic acid substituted on the 2-carbon of the ethyl ester group; structure; RN given refers to parent cpd	2.05	1	0	monocarboxylic acid
dexfenfluramine Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.	2.05	1	0	fenfluramine	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
synthalin a synthalin A: RN given refers to parent cpd; structure. synthalin : A hydrochloride resulting from the reaction of decamethylenediguanidine with 2 mol eq. of hydrogen chloride.. synthalin A : A member of the class of guanidines that is decane having guanidino groups at the 1- and 10-positions.	2.05	1	0	guanidines	hepatotoxic agent; hypoglycemic agent; nephrotoxin
isoimperatorin isoimperatorin: tumor necrosis factor antagonist isolated from Glehniae root. isoimperatorin : A member of the class of psoralens that is psoralen substituted by a prenyloxy group at position 5. Isolated from Angelica dahurica and Angelica koreana, it acts as a acetylcholinesterase inhibitor.	2.08	1	0	psoralens	EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite
suberosin suberosin: has anti-inflammatory activity. suberosin : A member of the class of coumarins in which the coumarin ring is substituted at positions 6 and 7 by a 3-methylbut-2-en-1-yl group and a methoxy group, respectively. A natural product found in Citropsis articulata.	2.08	1	0	aromatic ether; coumarins	anticoagulant; plant metabolite
ibopamine ibopamine: structure given in UD 31;67a & in 2nd source	2.05	1	0	benzoate ester; phenols
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.05	1	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
pirlindole pirlindole: RN given refers to parent cpd; synonym pyrazidol refers to mono-HCl; structure in Negwer, 5th ed, #2812	2.05	1	0	carbazoles
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	7.49	2	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
artemether Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.05	1	0	artemisinin derivative; cyclic acetal; organic peroxide; semisynthetic derivative; sesquiterpenoid	antimalarial
6-amino-1-hydroxyhexane-1,1-diphosphonate 6-amino-1-hydroxyhexane-1,1-diphosphonate: used for therapy of Paget's disease of bone & malignant hypercalcaemia	2.05	1	0	1,1-bis(phosphonic acid)
dexrazoxane Dexrazoxane: The (+)-enantiomorph of razoxane.	3.17	1	0	razoxane	antineoplastic agent; cardiovascular drug; chelator; immunosuppressive agent
rexigen clobenzorex: RN given refers to (+)-isomer; structure	2.05	1	0
buparvaquone buparvaquone: used in therapy of theileriasis; structure given in first source	3.31	1	0
aceclofenac [no description available]	2.05	1	0	amino acid; carboxylic ester; dichlorobenzene; monocarboxylic acid; secondary amino compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
clociguanil clociguanil: RN given refers to parent cpd; structure	2.05	1	0
tebuquine [no description available]	2.05	1	0
nobiletin nobiletin : A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively.	2	1	0	methoxyflavone	antineoplastic agent; plant metabolite
grepafloxacin grepafloxacin: structure in first source	3.17	1	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
gliclazide 18alpha-glycyrrhetinic acid: a gap junction inhibitor	2.13	1	0
indicine indicine: RN given refers to (1R-(1alpha,7(2R,3S),7abeta))-isomer	2.05	1	0	carboxylic ester; pyrrolizines
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	3.85	3	0	hydroxy-1,2-naphthoquinone
decane-1,2-diol decane-1,2-diol : A glycol that is decane bearing two hydroxy substituents located at positions 1 and 2.	2.41	1	0	glycol; volatile organic compound	anti-inflammatory agent; antioxidant; human metabolite
cryptolepine cryptolepine: fused indole-quinoline; structure in first source; from CRYPTOLEPIS sanguinolenta. cryptolepine : An organic heterotetracyclic compound that is 5H-indolo[3,2-b]quinoline in which the hydrogen at position N-5 is replaced by a methyl group.	2.05	1	0	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound	anti-inflammatory agent; antimalarial; antineoplastic agent; cysteine protease inhibitor; plant metabolite
carbetapentane citrate [no description available]	2.17	1	0	carbonyl compound
cinchonine [no description available]	2.05	1	0	(8xi)-cinchonan-9-ol; cinchona alkaloid	metabolite
n-hexadecyl-n,n-dimethyl-3-ammonio-1-propanesulfonate [no description available]	2.05	1	0
lopinavir [no description available]	3.17	1	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
desethylchloroquine desethylchloroquine: metabolite of chloroquine	2.05	1	0	aminoquinoline
mmv665852 MMV665852: an antischistosomal agent	3.35	1	0
wr 159412 [no description available]	2.05	1	0
cinchonidine cinchonidine: has antimalarial activity; diastereoisomer of cinchonine with distinct physiochemical properties; RN given refers to parent cpd(8alpha,9R)-isomer. cinchonidine : 8-epi-Cinchonan in which a hydrogen at position 9 is substituted by hydroxy (R configuration). A diasteroisomer of cinchonine, it occurs in the bark of most varieties of Cinchona shrubs, and is frequently used for directing chirality in asymmetric synthesis.	2.05	1	0	(8xi)-cinchonan-9-ol; cinchona alkaloid	metabolite
benzyloxyamine benzyloxyamine: RN given refers to parent cpd	2.05	1	0
diacetyldichlorofluorescein diacetyldichlorofluorescein: stable storage form of dichlorofluorescein	2.1	1	0
fluo-3 Fluo-3: fluorescent Ca(2+) indicator; permits continuous monitoring of Ca without interference with use of UV-sensitive caged compounds	2.11	1	0	xanthene dye	fluorochrome
pyronaridine [no description available]	2.05	1	0	aminoquinoline
gr 127935 GR 127935: a 5-HT 1D receptor antagonist. GR 127935 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid and the anilino group of 4-methoxy-3-(4-methylpiperazin-1-yl)aniline. Potent and selective 5-HT1B/1D receptor antagonist (pKi values are 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptors). Displays > 100-fold selectivity over 5HT1A, 5-HT2A, 5-HT2C receptors and other receptor types. Centrally active following oral administration.	3.35	1	0	1,2,4-oxadiazole; benzamides; N-alkylpiperazine; N-arylpiperazine
procyanidin Proanthocyanidins: Dimers and oligomers of flavan-3-ol units (CATECHIN analogs) linked mainly through C4 to C8 bonds to leucoanthocyanidins. They are structurally similar to ANTHOCYANINS but are the result of a different fork in biosynthetic pathways.	2.07	1	0	proanthocyanidin
parthenolide [no description available]	3.35	1	0	germacranolide
exp3174 losartan carboxylic acid: structure given in first source. losartan carboxylic acid : A biphenylyltetrazole that is losartan with the hydroxymethyl group at position 5 on the imidazole ring replaced with a carboxylic acid.	2.08	1	0	biphenylyltetrazole; imidazoles; organochlorine compound	metabolite
liquiritigenin liquiritigenin: structure given in first source; isolated from Pterocarpus marsupium. 4',7-dihydroxyflavanone : A dihydroxyflavanone in which the two hydroxy substituents are located at positions 4' and 7.. liquiritigenin : A dihydroxyflavanone compound having the two hydroxy substituents at the 4'- and 7-positions. Isolated from the root of Glycyrrhizae uralensis, it is a selective agonist for oestrogen receptor beta.	4.63	7	0	4',7-dihydroxyflavanone	hormone agonist; plant metabolite
tafenoquine tafenoquine : A racemate comprising equimolar amounts of (R)- and (S)-tafenoquine.. N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine : An aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group.	2.05	1	0	(trifluoromethyl)benzenes; aminoquinoline; aromatic ether; primary amino compound; secondary amino compound
marimastat marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary. marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.	3.51	1	0	hydroxamic acid; secondary carboxamide	antineoplastic agent; matrix metalloproteinase inhibitor
desethylamodiaquine desethylamodiaquine: metabolite of amodiaquine	2.05	1	0
n,n-dideethylchloroquine [no description available]	2.05	1	0
gefitinib [no description available]	7.41	1	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
glabridin [no description available]	9.71	8	0	hydroxyisoflavans	antiplasmodial drug
3,6-diamino-9-(4-(methylsulfonyl)aminophenyl)aminoacridine [no description available]	2.05	1	0
ne 58051 NE 58051: inhibits tumor cell adhesion to extracellular matrices; structure in first source	2.05	1	0
wr 242511 WR 242511: RN given refers to parent cpd	2.05	1	0
aspartame [no description available]	2.25	1	0	carboxylic acid; dipeptide zwitterion; dipeptide; methyl ester	apoptosis inhibitor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; environmental contaminant; micronutrient; nutraceutical; sweetening agent; xenobiotic
sinensetin sinensetin: isolated from citrus fruit; exhibit antiadhesive action on platelets. sinensetin : A pentamethoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 3' and 4' respectively.	3.51	1	0	pentamethoxyflavone	plant metabolite
tariquidar [no description available]	2.25	1	0	benzamides
oleanolic acid 3-acetate oleanolic acid 3-acetate: from Gardenia jasminoides; RN given for (3beta)-isomer	3.31	1	0
10-deacetylbaccatine iii 10-deacetylbaccatine III: structure given in first source	3.27	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	2.05	1	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.05	1	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
o 129 O 129: vibriostatic. 2,4-diamino-6,7-diisopropylpteridine : A member of the class of pteridines that is pteridine in which the hydrogens at positions 2 and 4 are replaced by amino groups, whilst those at positions 6 and 7 are replaced by isopropyl groups.. vibriostatic agent : Any compound that inhibits the growth of bacteria of the genus Vibrio.	3.27	1	0	primary amino compound; pteridines	antifolate; vibriostatic agent
tanshinone ii a tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source	3.31	1	0	abietane diterpenoid
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	7.21	1	0	amino acid zwitterion; angiotensin II	human metabolite
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.05	1	0
sb 203580 [no description available]	2.54	2	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
scutellarin scutellarin: see scutellarein for aglycone. scutellarin : The glycosyloxyflavone which is the 7-O-glucuronide of scutellarein.	3.51	1	0	glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antineoplastic agent; proteasome inhibitor
deflazacort deflazacort: structure	2.05	1	0	corticosteroid hormone
olpadronic acid [no description available]	2.05	1	0
sorafenib [no description available]	7.17	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.15	1	0
estramustine Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.	2.05	1	0	17beta-hydroxy steroid; carbamate ester; organochlorine compound	alkylating agent; antineoplastic agent; radiation protective agent
lupeol [no description available]	2.05	1	0	pentacyclic triterpenoid; secondary alcohol	anti-inflammatory drug; plant metabolite
bortezomib [no description available]	2.25	1	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
neocryptolepine neocryptolepine: isolated from the roots of the African plant Cryptolepis sanguinolenta; structure in first source	2.05	1	0
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.04	1	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
1-hydroxypentane-1,1-bisphosphonate [no description available]	2.05	1	0
cimadronate cimadronate: increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity; structure given in first source	2.05	1	0
1,1-hydroxyoctanodiphosphonate [no description available]	2.05	1	0
naringenin (S)-naringenin : The (S)-enantiomer of naringenin.	2.55	2	0	(2S)-flavan-4-one; naringenin	expectorant; plant metabolite
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	2.05	1	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
eriodictyol eriodictyol: structure. eriodictyol : A tetrahydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5, 7, 3' and 4' respectively.	2.25	1	0	3'-hydroxyflavanones; tetrahydroxyflavanone
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.05	1	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
monensin Monensin: An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies.. monensin A : A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle.	2.04	1	0	cyclic hemiketal; monocarboxylic acid; polyether antibiotic; spiroketal	antifungal agent; coccidiostat; ionophore
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.05	1	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	3.56	2	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
canaline canaline: structure	2.05	1	0	amino acid zwitterion; non-proteinogenic L-alpha-amino acid	antimetabolite; antineoplastic agent; phytogenic insecticide; plant metabolite
squamocin squamocin: from seeds of Annona squamosa; a trihydroxy-bis-tetrahydrofuran fatty acid lactone; inhibits E. coli NADH:quinone oxidoreductase (NDH-1); structure given in first source	3.1	1	0	polyketide
abyssinone i abyssinone I: anti-oxidant and cytotoxic compound from East African medicinal plant Erythrina abyssinica; structure in first source. abyssinone I : A monohydroxyflavanone that is (2S)-2',2'-dimethyl-2,3-dihydro-2'H,4H-2,6'-bichromen-4-one carrying a hydroxy substituent at position 7.	2.15	1	0	monohydroxyflavanone; phenols	apoptosis inhibitor; plant metabolite
asebogenin asebogenin: from Piper longicaudatum; structure in first source. asebogenin : A member of the class of dihydrochalcones that is the 4'-methyl ether derivative of phloretin.	3.13	1	0	dihydrochalcones	plant metabolite
ononin [no description available]	3.51	1	0	4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; monosaccharide derivative	plant metabolite
dioncophylline a dioncophylline A: derived from the tropical vine Triphyophyllum peltatum; structure given in first source. dioncophylline A : An isoquinoline alkaloid that is the biaryl resulting from substitution of the hydrogen at the 7-position of (1R,3R)-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-8-ol by a 4,5-dimethoxy-2-methylnaphthalen-1-yl group. It is a naphthylisoquinoline alkaloid isolated from the roots and stem barks of Triphyophyllum peltatum and exhibits antifungal, antimalarial, antineoplastic and molluscicidal activites.	3.17	1	0	biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes; naphthalenes	antifungal agent; antimalarial; metabolite; molluscicide
ergosterol [no description available]	2.15	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; ergostanoid; phytosterols	fungal metabolite; Saccharomyces cerevisiae metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.25	1	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
ferulic acid ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.	2	1	0	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	3.17	1	0
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	3.61	2	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
gw 3965 GW 3965: a liver X receptor ligand	3.35	1	0	diarylmethane
prostaglandin d2 Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).	2.13	1	0	prostaglandins D	human metabolite; mouse metabolite
roflumilast [no description available]	2.25	1	0	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.05	1	0	purvalanol
wr 225448 WR 225448: used as prophylaxis for Plasmodium yoelii infections; structure given in first source	3.17	1	0
halofuginone [no description available]	3.31	1	0
gamma-sitosterol clionasterol : A member of the class of phytosterols that is poriferast-5-ene carrying a beta-hydroxy substituent at position 3.	1.99	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; phytosterols	marine metabolite; plant metabolite
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.05	1	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.55	2	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
shikonin shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities	2.25	1	0	hydroxy-1,4-naphthoquinone
glabrene glabrene: structure in first source	2.15	1	0	isoflavonoid
6,8-diprenylgenistein 6,8-diprenylgenistein: a lysoPAF acetyltransferase inhibitor isolated from licorice root; structure in first source. 5,7,4'-trihydroxy-6,8-diprenylisoflavone : A member of the class of 7-hydroxyisoflavones that is genistein substituted by prenyl groups at positions 6 and 8. It has been isolated from Derris scandens and Glycyrrhiza uralensis.	2.55	2	0	7-hydroxyisoflavones	antibacterial agent; plant metabolite
Euchrestaflavanone A [no description available]	2.55	2	0	flavanones
likviriton liquiritin: isoalted from Glycyrrhizae radix. liquiritin : A flavanone glycoside that is liquiritigenin attached to a beta-D-glucopyranosyl residue at position 4' via a glycosidic linkage.	2.69	2	0	beta-D-glucoside; flavanone glycoside; monohydroxyflavanone; monosaccharide derivative	anti-inflammatory agent; anticoronaviral agent; plant metabolite
bromochloroacetic acid Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.. bromochloroacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by bromine while a second is replaced by chlorine. A low-melting (27.5-31.5degreeC), hygroscopic crystalline solid, it can be formed during the disinfection (by chlorination) of water that contains bromide ions and organic matter, so can occur in drinking water as a byproduct of the disinfection process.	2.41	1	0	2-bromocarboxylic acid; monocarboxylic acid; organochlorine compound
Tetrahydropiperine [no description available]	2.05	1	0	benzodioxoles
carbenoxolone [no description available]	2.05	1	0
rhapontin rhapontin: constituent of rhubarb rhizome	2.15	1	0	rhaponticin	angiogenesis inhibitor; anti-allergic agent; anti-inflammatory agent; antilipemic drug; antineoplastic agent; apoptosis inducer; EC 2.3.1.85 (fatty acid synthase) inhibitor; hypoglycemic agent; neuroprotective agent; plant metabolite
chalcone trans-chalcone : The trans-isomer of chalcone.	7.04	27	0	chalcone	EC 3.2.1.1 (alpha-amylase) inhibitor
piperine piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.	2.05	1	0	benzodioxoles; N-acylpiperidine; piperidine alkaloid; tertiary carboxamide	food component; human blood serum metabolite; NF-kappaB inhibitor; plant metabolite
2'-hydroxychalcone 2'-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 2'.	3.13	1	0	chalcones; phenols	anti-inflammatory agent
2,2'-dihydroxychalcone 2,2'-dihydroxychalcone: an antineoplastic agent; structure in first source	3.13	1	0
isoliquiritigenin [no description available]	6.62	16	0	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist
xanthohumol xanthohumol: from hop plant, Humulus lupulus. xanthohumol : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4', a methoxy group at position 6' and a prenyl group at position 3'. Isolated from Humulus lupulus, it induces apoptosis in human malignant glioblastoma cells.	4.42	3	0	aromatic ether; chalcones; polyphenol	anti-HIV-1 agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor; metabolite
ilepcimide ilepcimide: structure given in first source; RN given refers to compound with no isomeric designation	2.05	1	0	benzodioxoles
cardamonin cardamonin: found in Zingiberaceae; structure in first source	4.99	4	0	chalcones
polidocanol Polidocanol: An alkyl polyglycol ether of LAURYL ALCOHOL, chemically defined as an alcohol ethoxylate having an average alkyl chain of 12–14 carbon atoms, and an ethylene oxide chain of 9 ethylene oxide units. It is used as a detergent, and medically as a local anesthetic, and as a sclerosing agent for the treatment of ESOPHAGEAL AND GASTRIC VARICES and VARICOSE VEINS.. polidocanol : A hydroxypolyether that is nonaethylene glycol in which one of the terminal hydroxy functions is substituted by a lauryl (dodecyl) group.	3.47	1	1	hydroxypolyether	hepatotoxic agent; nonionic surfactant; sclerotherapy agent
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.05	1	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
octotropine methylbromide octotropine methylbromide: minor descriptor (65-86); on line & INDEX MEDICUS search TROPANES (69-86); RN given refers to endo-isomer. anisotropine methylbromide : A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide.	2.05	1	0
ipratropium bromide anhydrous [no description available]	2.05	1	0
caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid.	7.15	1	0	caffeic acid	geroprotector; mouse metabolite
flunarizine Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.	2.05	1	0	diarylmethane
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.55	2	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	2.05	1	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	3.51	1	1	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
umbelliprenin umbelliprenin: RN given refers to cpd with unspecified isomeric designation	2.13	1	0	terpene lactone
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.05	1	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
tamoxifen [no description available]	3.31	1	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.	2.05	1	0	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
stattic [no description available]	3.35	1	0	1-benzothiophenes; C-nitro compound; sulfone	antineoplastic agent; radiosensitizing agent; STAT3 inhibitor
artemotil artemotil: structure given in first source; RN given refers to cpd without isomeric designation	2.05	1	0	artemisinin derivative
thiophanate Thiophanate: Nematocide used in livestock; also has fungicidal properties.. thiophanate : A member of the class of thioureas that is the diethyl ester of (1,2-phenylenedicarbamothioyl)biscarbamic acid. A fungicide effective against a broad spectrum of diseases in fruit, vegetables, turf and other crops including eyespot, scab, powdery mildew and grey mould.	2.04	1	0	benzimidazole precursor fungicide; carbamate ester; carbamate fungicide; thioureas	antifungal drug
enpiroline enpiroline: structure	3.35	1	0
gestodene Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer	2.05	1	0	steroid	estrogen
glucametacin glucametacin: indomethacin analog; structure	2.05	1	0
quinine [no description available]	2.05	1	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
e 7010 E 7010: inhibits tubulin polymerization; structure given in first source	2.25	1	0	sulfonamide
cytellin cytellin: a phytosterol preparation of mainly B-sitosterol, that was marketed by Eli Lilly to lower cholesterol 1957 to 1982	1.99	1	0
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.21	1	0
fh535 FH535: inhibits Wnt signaling	2.25	1	0	sulfonamide
ML162 ML162 : A monochlorobenzene that is benzene substituted by (chloroacetyl){2-oxo-2-[(2-phenylethyl)amino]-1-(thiophen-2-yl)ethyl}amino, chloro and methoxy groups at positions 1, 3 and 4, respectively. It is a covalent inhibitor of glutathione peroxidase 4 (GPX4) that induces ferroptosis in cells.	2.25	1	0	monochlorobenzenes; monomethoxybenzene; organochlorine compound; secondary carboxamide; tertiary carboxamide; thiophenes	EC 1.11.1.9 (glutathione peroxidase) inhibitor; ferroptosis inducer
rs 17053 [no description available]	3.35	1	0	indoles
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	2.25	1	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
rhodamine 123 Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.	2.08	1	0	organic cation; xanthene dye	fluorochrome
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.05	1	0	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
5,6-dehydrokawain 5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source	2.08	1	0	2-pyranones; aromatic ether
quercetin [no description available]	4.55	3	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	5.11	5	2	prostaglandins E	human metabolite; mouse metabolite; oxytocic
formononetin [no description available]	3.06	4	0	4'-methoxyisoflavones; 7-hydroxyisoflavones	phytoestrogen; plant metabolite
acacetin 5,7-dihydroxy-4'-methoxyflavone : A monomethoxyflavone that is the 4'-methyl ether derivative of apigenin.	7.31	1	0	dihydroxyflavone; monomethoxyflavone	anticonvulsant; plant metabolite
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	3.31	1	0	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	9.75	4	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
quercitrin [no description available]	3.31	1	0	alpha-L-rhamnoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	antileishmanial agent; antioxidant; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; plant metabolite
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	3.41	1	1	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
2'-hydroxyformononetin 2'-hydroxyformononetin : A member of the class of 4'-methoxyisoflavones that is formononetin with a hydroxy group at the 2'position.	2.55	2	0	4'-methoxyisoflavones; 7-hydroxyisoflavones	anti-inflammatory agent
alprostadil [no description available]	2.05	1	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
quercetin 3-o-glucopyranoside quercetin 3-O-glucopyranoside: structure in first source. quercetin 3-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells	3.31	1	0	beta-D-glucoside; monosaccharide derivative; quercetin O-glucoside; tetrahydroxyflavone	antineoplastic agent; antioxidant; antipruritic drug; bone density conservation agent; geroprotector; histamine antagonist; osteogenesis regulator; plant metabolite
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	3.31	1	0	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
kaempferol [no description available]	3.73	2	0	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
genistein [no description available]	4.66	4	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	3.87	3	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
butein [no description available]	3.82	3	0	chalcones; polyphenol	antineoplastic agent; antioxidant; EC 1.1.1.21 (aldehyde reductase) inhibitor; geroprotector; hypoglycemic agent; plant metabolite; radiosensitizing agent; tyrosine kinase inhibitor
isobavachalcone isobavachalcone: RN given for (E)-isomer; structure in first source. isobavachalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'.	4.82	5	0	chalcones; polyphenol	antibacterial agent; metabolite; platelet aggregation inhibitor
Rhynchophylline [no description available]	2.15	1	0	indolizines	metabolite
usambarensine usambarensine: structure given in first source	2.05	1	0	harmala alkaloid
isoplumericin isoplumericin: isolated from Plumeria rubra	3.27	1	0	terpene lactone
plumericin plumericin: from bark of Plumeria rubra; structure given in first source; RN given refers to (3aS-(3E,3aalpha,4abeta,7abeta,9aR*,9bbeta))-isomer; RN for cpd without isomeric designation not avail 5/91	3.27	1	0	terpene lactone
apigenin dimethylether apigenin dimethylether: a dimethoxy analog of apigenin from roots of Rhus undulata and possibly other plants. apigenin 7,4'-dimethyl ether : A dimethoxyflavone that is the 7,4'-dimethyl ether derivative of apigenin.	3.31	1	0	dimethoxyflavone; monohydroxyflavone	plant metabolite
baicalein [no description available]	3.31	1	0	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
fisetin [no description available]	3.31	1	0	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
galangin 5,7-dihydroxyflavonol: antimicrobial from the twigs of Populus nigra x Populus deltoides; structure in first source. galangin : A 7-hydroxyflavonol with additional hydroxy groups at positions 3 and 5 respectively; a growth inhibitor of breast tumor cells.	3.73	2	0	7-hydroxyflavonol; trihydroxyflavone	antimicrobial agent; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; plant metabolite
hyperoside quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity.	3.31	1	0	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite
mangiferin shamimin: isolated from the leaves of Bombax ceiba; structure in first source	3.51	1	0	C-glycosyl compound; xanthones	anti-inflammatory agent; antioxidant; hypoglycemic agent; plant metabolite
kaempferide kaempferide: structure in first source. kaempferide : A monomethoxyflavone that is the 4'-O-methyl derivative of kaempferol.	2.25	1	0	7-hydroxyflavonol; monomethoxyflavone; trihydroxyflavone	antihypertensive agent; metabolite
morin morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.	2.25	1	0	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
myricetin [no description available]	3.31	1	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
myricitrin myricitrin: isolated from root bark of Myrica cerifera L.; structure. myricitrin : A glycosyloxyflavone that consists of myricetin attached to a alpha-L-rhamnopyranosyl residue at position 3 via a glycosidic linkage. Isolated from Myrica cerifera, it exhibits anti-allergic activity.	3.31	1	0	alpha-L-rhamnoside; glycosyloxyflavone; monosaccharide derivative; pentahydroxyflavone	anti-allergic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; plant metabolite
scutellarein scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.	2.25	1	0	tetrahydroxyflavone	metabolite
wogonin wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.	3.73	2	0	dihydroxyflavone; monomethoxyflavone	angiogenesis inhibitor; antineoplastic agent; cyclooxygenase 2 inhibitor; plant metabolite
daidzein [no description available]	2.25	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
polydatin trans-piceid : A stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue.	2.15	1	0	beta-D-glucoside; monosaccharide derivative; polyphenol; stilbenoid	anti-arrhythmia drug; antioxidant; geroprotector; hepatoprotective agent; metabolite; nephroprotective agent; potassium channel modulator
cynarine cynarine: active principle of the artichoke; functions primarily as a cholagogue and choleretic and also as antilipemic agent	2.05	1	0	alkyl caffeate ester; quinic acid	plant metabolite
licoisoflavone a licoisoflavone A: from Sophra mooracroftiana; structure in first source. licoisoflavone A : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone substituted by additional hydroxy groups at positions 5, 2' and 4' and a prenyl group at position 3'.	2.55	2	0	7-hydroxyisoflavones	metabolite
shogaol shogaol: from ginger, ZINGIBER OFFICINALE; less mutagenic than GINGEROL; structure given in first source	3.31	1	0	enone; monomethoxybenzene; phenols
wighteone wighteone : A member of the class of 7-hydroxyisoflavones that is isoflavone substituted by hydroxy groups at positions 5, 7 and 4' and a prenyl group at position 6. It has been isolated from Ficus mucuso.	2.55	2	0	7-hydroxyisoflavones	antifungal agent; plant metabolite
l 660,711 [no description available]	2.25	1	0	quinolines
4',7-dihydroxyflavone 4',7-dihydroxyflavone: inducer of nod gene. 4',7-dihydroxyflavone : A dihydroxyflavone in which the two hydroxy substituents are located at positions 4' and 7.	2.55	2	0	dihydroxyflavone	metabolite
4-hydroxychalcone 4-hydroxychalcone: structure in first source. 4-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 4.	3.21	1	0	chalcones; phenols	antihypertensive agent; plant metabolite
4'-hydroxychalcone 4'-hydroxychalcone: inhibits TNFalpha-induced NF-κB activation; structure in first source. 4'-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 4'.	2.44	2	0	chalcones; phenols	anti-inflammatory agent; antineoplastic agent
triprolidine Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.	2.05	1	0	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
codeine [no description available]	2.05	1	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
dihydrocodeine dihydrocodeine: RN refers to parent cpd(5alpha,6alpha)-isomer	2.05	1	0	morphinane alkaloid
ly 163892 loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.	2.05	1	0	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	2.05	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.66	2	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
3',4',7-trihydroxyisoflavone 3',4',7-trihydroxyisoflavone: from Streptomyces sp OH-1049; structure given in first source. 3',4',7-trihydroxyisoflavone : A 7-hydroxyisoflavone that is daidzein substituted by a hydroxy group at position 3'.	2.15	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor; metabolite
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.05	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
lacidipine [no description available]	2.05	1	0	cinnamate ester; tert-butyl ester
vinorelbine [no description available]	2.05	1	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent
2',6'-dihydroxy-4'-methoxychalcone 2',6'-dihydroxy-4'-methoxychalcone: isolated from Piper aduncum; structure in first source	4.73	3	0	chalcones
lupiwighteone lupiwighteone: has antineoplastic activity; structure in first source	2.55	2	0	isoflavones
eurycarpin b eurycarpin B: from the roots of Glycyrrhiza eurycarpa; structure in first source	2.84	3	0	isoflavonoid
glycycoumarin glycycoumarin: from the root of Glycyrrhizae Radix, acts as a potent antispasmodic through inhibition of phosphodiesterase 3; structure in first source. glycycoumarin : A member of the class of coumarins that is coumarin substituted by a hydroxy group at position 7, a methoxy group at position 5, a prenyl group at position 6 and a 2,4-dihydroxyphenyl group at position 3. Isolated from Glycyrrhiza uralensis, it exhibits antispasmodic activity.	2.48	2	0	aromatic ether; coumarins; resorcinols	antispasmodic drug; plant metabolite
licochalcone b licochalcone B: isolated from Glycyrrhiza inflata; inhibits phosphorylation of NF-kappaB p65 in LPS signaling pathway; structure in first source	3.4	6	0	chalcones
Licoflavone A [no description available]	2.85	3	0	flavones
7,4'-dihydroxy-3'-methoxyisoflavone 7,4'-dihydroxy-3'-methoxyisoflavone : A member of the class of 7-hydroxyisoflavones that is 7,4'-dihydroxyisoflavone substituted by a methoxy group at position 3'. It is isolated from the heart woods of Maackia amurensis subsp buergeri and Dalbergia louveli and exhibits antiplasmodial ativity.	2.15	1	0	7-hydroxyisoflavones; methoxyisoflavone	antiplasmodial drug; metabolite
apigenin-7-o-beta-d-glucuronide [no description available]	3.31	1	0	flavonoids; glucosiduronic acid
neoglycyrol neoglycyrol: structure given in first source; from Glycyrrhiza uralensis Fisch. glycyrol : A member of the class of coumestans that is coumestan substituted by hydroxy groups at positions 1 and 9, a methoxy group at position 3 and a prenyl group at position 2 respectively.	2.21	1	0	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; plant metabolite
2'-hydroxy-4-methoxychalcone [no description available]	3.35	1	0
nifuroxazide nifuroxazide: structure	2.25	1	0	benzoic acids
stilbamidine stilbamidine: RN given refers to parent cpd	2.05	1	0
guttiferone e guttiferone E: isolated from the fruits of Garcinia pyrifera collected in Malaysia; structure in first source	3.31	1	0
flavokawain b flavokawain B: from Piper methysticum Forst (Kava Kava) roots; structure in first source. flavokawain B : A member of the class of chalcones that consists of trans-chalcone substituted by hydroxy group at positions 2' and methoxy groups at positions 4' and 6'. Isolated from Piper methysticum and Piper rusbyi, it exhibits antileishmanial, anti-inflammatory and antineoplastic activities.	3.62	2	0	chalcones; dimethoxybenzene; phenols	anti-inflammatory agent; antileishmanial agent; antineoplastic agent; apoptosis inducer; metabolite
Isoliquiritigenin 4,4'-dimethyl ether [no description available]	2.15	1	0	chalcones
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	2.04	1	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
geldanamycin [no description available]	7.08	1	0
piperic acid piperinic acid: from Piper longum; structure in first source. (E,E)-piperic acid : A monocarboxylic acid that is (E)-penta-2,4-dienoic acid substituted by a 1,3-benzodioxol-5-yl group at position 5. It has been isolated from black pepper (Piper nigrum).	2.05	1	0	alpha,beta-unsaturated monocarboxylic acid; benzodioxoles	plant metabolite
grifolin grifolin: antibiotic isolated from Grifola confluens	2.6	1	0	sesquiterpenoid
2',4'-dihydroxychalcone 2',4'-dihydroxychalcone: RN given refers to (E)-isomer; RN for cpd without isomeric designation not available 6/89; structure given in first source	4.1	2	0
4,4'-dichlorochalcone 4,4'-dichlorochalcone: structure in first source	2.05	1	0
4-chlorochalcone 4-chlorochalcone : A member of the class of chalcones that is trans-chalcone substituted by a chloro group at position 4.	3.13	1	0	chalcones; monochlorobenzenes
aldosterone dehydrodiisoeugenol: an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages; structure in first source	3.35	1	0
4,4'-dihydroxychalcone 4,4'-dihydroxychalcone: structure	1.99	1	0
licoisoflavone b licoisoflavone B: from Sophra mooracroftiana; structure in first source	2.55	2	0
semilicoisoflavone b semilicoisoflavone B: isolated from Glycyrrhiza uralensis; structure in first source. semilicoisoflavone B : A member of the class of 7-hydroxyisoflavones that is 2',2'-dimethyl-2'H,4H-3,6'-bichromen-4-one substituted by hydroxy groups at positions 5, 7 and 8'. It has been isolated from Glycyrrhiza uralensis.	2.55	2	0	7-hydroxyisoflavones	EC 1.1.1.21 (aldehyde reductase) inhibitor; plant metabolite
avicularin avicularin: from Polygonum aviculare L.; RN given refers to L-isomer. avicularin : A quercetin O-glycoside in which an alpha-L-arabinofuranosyl residue is attached at position 3 of quercetin via a glycosidic linkage. It is isolated particularly from Juglans regia and Foeniculum vulgare.	3.31	1	0	alpha-L-arabinofuranoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite
alpinumisoflavone alpinumisoflavone: extract from twigs of poisonous British plant	2.55	2	0	isoflavanones	metabolite
quercetin 7-rhamnoside quercetin 7-rhamnoside: has antiviral activity against porcine epidemic diarrhea virus. quercetin 7-O-alpha-L-rhamnopyranoside : A quercetin O-glycoside that is quercetin attached to a alpha-L-rhamnopyranosyl moiety at position 7 via a glycosidic linkage.	3.31	1	0	alpha-L-rhamnoside; flavonols; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	metabolite
4-hydroxylonchocarpin 4-hydroxylonchocarpin: structure in first source	3.13	1	0
2-chloro-4',6'-dimethoxy-2'-hydroxychalcone 2-chloro-4',6'-dimethoxy-2'-hydroxychalcone: induces glutathione biosynthesis; structure in first source	4.08	2	0
proguanil Proguanil: A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.. proguanil : A biguanide compound which has isopropyl and p-chlorophenyl substituents on the terminal N atoms. A prophylactic antimalarial drug, it works by inhibiting the enzyme dihydrofolate reductase, which is involved in the reproduction of the malaria parasites Plasmodium falciparum and P. vivax within the red blood cells.	2.05	1	0	biguanides; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	2.11	1	0	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
3-o-methylbutein 3-O-methylbutein: RN given refers to (E)-isomer; structure given in first source	3.51	2	0	chalcones
ro 09-0410 Ro 09-0410: structure given in first source	3.21	1	0
everolimus [no description available]	2.25	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
eupomatenoid 5 eupomatenoid 5: RN given for (E)-isomer; structure in first source	3.27	1	0
ekb 569 EKB 569: an EGF receptor kinase inhibitor	3.35	1	0	aminoquinoline; monocarboxylic acid amide; monochlorobenzenes; nitrile	protein kinase inhibitor
2',4',6'-trihydroxychalcone pinocembrin chalcone: isolated from Helichrysum trilineatum; structure in first source. pinocembrin chalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 2', 4' and 6' respectively.	3.13	1	0	chalcones	antifungal agent; plant metabolite
3 beta-o-acetylursolic acid [no description available]	3.31	1	0	triterpenoid
nifuroxime 5-nitro-2-furaldehyde oxime: structure in first source	2.05	1	0
1-methyl-d-lysergic acid butanolamide [no description available]	2.05	1	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
nifurtimox Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.	2.49	2	0	nitrofuran antibiotic
ispinesib [no description available]	3.35	1	0	benzamides
butylscopolammonium bromide Butylscopolammonium Bromide: Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.	2.05	1	0
roxithromycin (E)-roxithromycin : A major geometrical isomer of roxithromycin.	2.05	1	0	roxithromycin	environmental contaminant; xenobiotic
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.05	1	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
chlorproguanil chlorproguanil: dichloro-derivative of chloroguanide; RN given refers to parent cpd; structure	2.05	1	0	dichlorobenzene
jasplakinolide jasplakinolide: cyclodepsipeptide isolated from marine sponge Jaspis; active against Candida; RN refers to 2S-(2R,4E,6S,8R*)-isomer; structure in first source. jaspamide : A cyclodepsipeptide isolated from Jaspis splendens and has been shown to exhibit antineoplastic activity. It is an actin polymerization and stabilization inducer.	3.31	1	0	cyclodepsipeptide; phenols	actin polymerisation inducer; animal metabolite; antifungal agent; antineoplastic agent; apoptosis inducer; marine metabolite; neuroprotective agent
licochalcone c licochalcone C: has cardioprotective, antioxidant, anti-inflammatory and anti-apoptotic activities; isolated from licorice; structure in first source	3.02	4	0
ripasudil [no description available]	2.25	1	0	isoquinolines
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.17	1	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
n1-phenyl-3,5-dinitro-n4,n4-di-n-propylsulfanilamide N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide: a potent, selective antimitotic agent against kinetoplastid parasites; structure in first source	2.05	1	0
1,2,6,7-tetraoxaspiro(7.11)nonadecane 1,2,6,7-tetraoxaspiro(7.11)nonadecane: structure in first source	3.35	1	0
artenimol artenimol: derivative of antimalarial drug artemisinin (quinghaosu)	2.05	1	0
licoflavone c licoflavone C: Antimutagenic Agent; a naturally occurring prenyl-flavone extracted from Genista ephedroides; structure in first source	3.96	3	0
4-phenoxyphenoxyethyl thiocyanate 4-phenoxyphenoxyethyl thiocyanate: has antiparasitic activity; structure in first source	2.05	1	0
sd-208 [no description available]	3.35	1	0
ly 411575 [no description available]	3.17	1	0	dibenzoazepine; difluorobenzene; lactam; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor
licochalcone d licochalcone D: isolated from Glycyrrhiza inflata; inhibits phosphorylation of NF-kappaB p65 in LPS signaling pathway	8.2	5	0
Kanzonol B [no description available]	2.84	3	0	chalcones
epoxomicin [no description available]	3.56	2	0	morpholines; tripeptide	proteasome inhibitor
2',3,4,4'-tetrahydroxy-5-prenylchalcone [no description available]	3.55	2	0
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	2.06	1	0	nystatins
Licoflavone B licoflavone B: Schistosomicide from Glycyrrhiza inflata; structure in first source	2.55	2	0	flavones
bi 2536 [no description available]	3.35	1	0
glabrol glabrol: from Glycyrrhiza glabra hairy root; structure in first source	2.75	3	0	flavanones
diflucortolone Diflucortolone: A topical glucocorticoid used in various DERMATOSES. It is absorbed through the skin, bound to plasma albumin, and may cause adrenal suppression. It is also administered as the valerate.	2.05	1	0	21-hydroxy steroid
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.25	1	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
11-deoxy glycyrrhetinic acid [no description available]	2.15	1	0	triterpenoid
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	2.08	1	0
deoxoartemisinin deoxoartemisinin: structure given in first source	2.05	1	0
derrone derrone: from Retama raetam flowers; structure in first source	3.68	2	0	isoflavonoid
amodiaquine hydrochloride [no description available]	2.05	1	0
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.45	2	0
cnf 2024 [no description available]	2.25	1	0	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor
valproate sodium Epilim: oral sodium valproate used as antidepressive agent. sodium valproate : The sodium salt of valproic acid.. valproate : A branched-chain saturated fatty acid anion that is the conjugate base of valproic acid.	2.05	1	0	organic sodium salt	geroprotector
ubiquinone Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.	2.02	1	0
isoangustone a isoangustone A: antioxidant isolated from Glycyrrhiza uralensis; structure in first source	2.17	1	0	isoflavanones
3mb-pp1 [no description available]	3.31	1	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.07	1	0
nitd 609 NITD 609: an antimalarial and coccidiostat; structure in first source	3.31	1	0
licochalcone e licochalcone E: from roots of Glycyrrhiza inflata; structure in first source	3.37	6	0
butyrolactone i butyrolactone I: selective inhibitor of cdk2 & cdc2 kinase; structure given in first source	2.05	1	0	butenolide
pf-4708671 [no description available]	2.25	1	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.49	2	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	3.57	2	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	2.05	1	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	2.05	1	0
piroxicam [no description available]	2.05	1	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	2.25	1	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.	2.05	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	3.81	3	0	benzenes; hydroxycoumarin; methyl ketone
ferulenol ferulenol: intoxicating component of powdered Ferula communis variety brevifolia; RN given for (E,E)-isomer	2.08	1	0
rolitetracycline Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.	2.05	1	0
bms-833923 BMS-833923: an Smo inhibitor	3.35	1	0
millepachine millepachine: isolated from Millettia pachycarpa Benth (Leguminosae); structure in first source	3.31	1	0
longikaurin a longikaurin A: from Isodon adenolomus; structure in first source	3.31	1	0	kaurane diterpenoid	metabolite
(r)-pfi-2 (R)-PFI-2: a potent and selective inhibitor of SETD7 methyltransferase; structure in first source	2.25	1	0
osimertinib osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.	2.31	1	0	acrylamides; aminopyrimidine; biaryl; indoles; monomethoxybenzene; secondary amino compound; secondary carboxamide; substituted aniline; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.6	1	0
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	2.1	1	0
isomurisolenin isomurisolenin: an acetogenin from seeds of Annona reticulata;	3.1	1	0
3-methyladenine N3-methyladenine: structure in first source	2.11	1	0
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	4.06	4	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.05	1	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
zaprinast zaprinast: anaphylaxis inhibitor; structure	3.31	1	0	triazolopyrimidines
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.05	1	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
thiolactomycin thiolactomycin: from actinomycetes; structure given in first source	2.05	1	0
3,4,5-trihydroxybenzamidoxime 3,4,5-trihydroxybenzamidoxime: structure given in first source	2.05	1	0	benzenetriol
nms-e973 NMS-E973: structure in first source	2.25	1	0

Condition	Relationship Strength	Studies	Trials
Extravascular Hemolysis [description not available]	2.97	4	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.97	4	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.42	2	0
Parasite Infections [description not available]	2.05	1	0
Infections, Plasmodium [description not available]	3.33	2	0
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	8.33	2	0
Acute Liver Injury, Drug-Induced [description not available]	2.58	2	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.94	11	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.58	2	0
Cough A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.	2.17	1	0
Fungal Diseases [description not available]	3.12	1	0
Mycoses Diseases caused by FUNGI.	3.12	1	0
Benign Neoplasms [description not available]	3.12	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.12	1	0
Infection, Toxoplasma gondii [description not available]	3.12	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	3.12	1	0
Toxoplasmosis The acquired form of infection by Toxoplasma gondii in animals and man.	3.12	1	0
Sarcoma, Epithelioid [description not available]	2.25	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	7.25	1	0
Degenerative Diseases, Central Nervous System [description not available]	2.25	1	0
Atherogenesis [description not available]	2.25	1	0
Osseous Paget's Disease [description not available]	2.25	1	0
Osteitis Deformans A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry.	2.25	1	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.25	1	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.25	1	0
Bone Cancer [description not available]	3.78	3	0
Osteogenic Sarcoma [description not available]	3.86	3	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	3.78	3	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	3.86	3	0
Allergic Reaction [description not available]	7.31	1	0
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	2.31	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.63	2	0
Alloxan Diabetes [description not available]	2.96	3	0
Diabetes Mellitus, Adult-Onset [description not available]	2.72	2	0
Diabetic Glomerulosclerosis [description not available]	2.31	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.72	2	0
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.31	1	0
Kahler Disease [description not available]	2.31	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	2.31	1	0
Cirrhosis, Liver [description not available]	2.31	1	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	2.31	1	0
Cholangiocellular Carcinoma [description not available]	2.82	2	0
Bile Duct Cancer [description not available]	2.82	2	0
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	2.82	2	0
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	2.82	2	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	7.31	1	0
2019 Novel Coronavirus Disease [description not available]	2.41	1	0
Carcinoma, Non-Small Cell Lung [description not available]	3.34	5	0
Cancer of Lung [description not available]	3.81	9	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	3.34	5	0
Lung Neoplasms Tumors or cancer of the LUNG.	3.81	9	0
Acne [description not available]	8.55	8	6
Dermatitis Seborrheica [description not available]	2.41	1	0
Acne Vulgaris A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.	8.55	8	6
Dermatitis, Seborrheic A chronic inflammatory disease of the skin with unknown etiology. It is characterized by moderate ERYTHEMA, dry, moist, or greasy (SEBACEOUS GLAND) scaling and yellow crusted patches on various areas, especially the scalp, that exfoliate as dandruff. Seborrheic dermatitis is common in children and adolescents with HIV INFECTIONS.	2.41	1	0
Lung Injury, Acute [description not available]	3.69	7	0
Innate Inflammatory Response [description not available]	4.09	12	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	4.09	12	0
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	3.69	7	0
Choroid Neovascularization [description not available]	4.21	9	0
Acute Respiratory Distress Syndrome [description not available]	3.52	4	0
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	3.52	4	0
Carcinoma, Epidermoid [description not available]	4.18	5	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	4.18	5	0
Acute Confusional Senile Dementia [description not available]	3.93	2	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	3.93	2	0
Nerve Pain [description not available]	2.82	2	0
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	2.82	2	0
Infections, Respiratory Syncytial Virus [description not available]	2.6	1	0
Respiratory Syncytial Virus Infections Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported.	2.6	1	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	7.6	1	0
Cancer of Esophagus [description not available]	2.6	1	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	2.6	1	0
Colorectal Cancer [description not available]	8.1	4	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.1	4	0
Malignant Melanoma [description not available]	2.25	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	7.25	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.25	1	0
Arthritis, Degenerative [description not available]	2.59	2	0
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	7.59	2	0
Cancer of Colon [description not available]	3.21	5	0
Colonic Neoplasms Tumors or cancer of the COLON.	3.21	5	0
Chronic Illness [description not available]	2.31	1	0
Constriction, Pathological [description not available]	2.31	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.31	1	0
Constriction, Pathologic The condition of an anatomical structure's being constricted beyond normal dimensions.	2.31	1	0
Insulin Sensitivity [description not available]	2.31	1	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.31	1	0
Experimental Neoplasms [description not available]	2.52	2	0
Enterovirus Infections Diseases caused by ENTEROVIRUS.	2.31	1	0
Hand Foot and Mouth Disease [description not available]	2.31	1	0
Hand, Foot and Mouth Disease A mild, highly infectious viral disease of children, characterized by vesicular lesions in the mouth and on the hands and feet. It is caused by coxsackieviruses A.	2.31	1	0
Colitis Gravis [description not available]	2.63	2	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	7.31	1	0
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	2.63	2	0
Breast Cancer [description not available]	3.23	5	0
Breast Neoplasms Tumors or cancer of the human BREAST.	3.23	5	0
Asthma, Bronchial [description not available]	3.04	4	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	3.04	4	0
Acne Rosacea [description not available]	4.16	3	1
Dermatoses [description not available]	2.15	1	0
Rosacea A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).	4.16	3	1
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	2.15	1	0
Blood Clot [description not available]	2.15	1	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.15	1	0
Idiopathic Parkinson Disease [description not available]	2.15	1	0
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	2.15	1	0
Injury, Ischemia-Reperfusion [description not available]	2.17	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.17	1	0
Absence Seizure [description not available]	2.17	1	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	2.17	1	0
Adjuvant Arthritis [description not available]	2.58	2	0
Rheumatoid Arthritis [description not available]	2.58	2	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.58	2	0
Cancer of Stomach [description not available]	3.02	4	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	3.02	4	0
Facial Dermatoses Skin diseases involving the FACE.	4.5	2	2
Hepatocellular Carcinoma [description not available]	3.25	5	0
Cancer of Liver [description not available]	3.38	6	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	3.25	5	0
Liver Neoplasms Tumors or cancer of the LIVER.	3.38	6	0
Toxoplasmosis, Animal Acquired infection of non-human animals by organisms of the genus TOXOPLASMA.	2.17	1	0
Glial Cell Tumors [description not available]	2.58	2	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.58	2	0
Diseases, Metabolic [description not available]	2.17	1	0
Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)	2.17	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.59	2	0
Adenocarcinoma Of Kidney [description not available]	2.17	1	0
Cancer of Kidney [description not available]	2.17	1	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	2.17	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.17	1	0
Abdominal Aortic Aneurysm [description not available]	7.21	1	0
Aortic Aneurysm, Abdominal An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.	2.21	1	0
Invasiveness, Neoplasm [description not available]	2.53	2	0
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	7.21	1	0
Cancer of Nasopharynx [description not available]	2.21	1	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	2.21	1	0
Fatty Liver, Nonalcoholic [description not available]	2.21	1	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	7.21	1	0
Airway Hyper-Responsiveness [description not available]	7.21	1	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.21	1	0
Itching [description not available]	3.47	1	1
Scalp Dermatoses Skin diseases involving the SCALP.	3.47	1	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	3.47	1	1
Bladder Cancer [description not available]	2.79	3	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.79	3	0
Eczema, Atopic [description not available]	4.42	2	2
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	4.42	2	2
Cancer of Pancreas [description not available]	2.1	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.1	1	0
Cancer of Mouth [description not available]	3.01	4	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	3.01	4	0
Allergic Encephalomyelitis [description not available]	2.1	1	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	2.1	1	0
Infections, Helicobacter [description not available]	2.1	1	0
Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.	2.1	1	0
Autosomal Dominant Striatonigral Degeneration [description not available]	2.1	1	0
Machado-Joseph Disease A dominantly-inherited ATAXIA first described in people of Azorean and Portuguese descent, and subsequently identified in Brazil, Japan, China, and Australia. This disorder is classified as one of the SPINOCEREBELLAR ATAXIAS (Type 3) and has been associated with a mutation of the MJD1 gene on chromosome 14. Clinical features include progressive ataxia, DYSARTHRIA, postural instability, nystagmus, eyelid retraction, and facial FASCICULATIONS. DYSTONIA is prominent in younger patients (referred to as Type I Machado-Joseph Disease). Type II features ataxia and ocular signs; Type III features MUSCULAR ATROPHY and a sensorimotor neuropathy; and Type IV features extrapyramidal signs combined with a sensorimotor neuropathy. (From Clin Neurosci 1995;3(1):17-22; Ann Neurol 1998 Mar;43(3):288-96)	2.1	1	0
Metastase [description not available]	2.49	2	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.49	2	0
Carcinoma, Squamous Cell of Head and Neck [description not available]	3.03	1	0
Cancer of Head [description not available]	3.03	1	0
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	3.03	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	3.03	1	0
Malignant Mesothelioma [description not available]	2.11	1	0
Neoplasms, Pleural [description not available]	2.11	1	0
Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)	7.11	1	0
Cancer of Cervix [description not available]	2.11	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.11	1	0
Acute Kidney Failure [description not available]	2.13	1	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	7.13	1	0
Ache [description not available]	3.51	1	1
Sensation Disorders Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).	3.51	1	1
Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.	5.28	4	3
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	3.51	1	1
Spider Veins [description not available]	2.13	1	0
Telangiectasis Permanent dilation of preexisting blood vessels (CAPILLARIES; ARTERIOLES; VENULES) creating small focal red lesions, most commonly in the skin or mucous membranes. It is characterized by the prominence of skin blood vessels, such as vascular spiders.	2.13	1	0
Moniliasis, Oral [description not available]	2.13	1	0
Candidiasis, Oral Infection of the mucous membranes of the mouth by a fungus of the genus CANDIDA. (Dorland, 27th ed)	2.13	1	0
Bone Loss, Osteoclastic [description not available]	2.46	2	0
Endotoxin Shock [description not available]	7.04	1	0
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	2.04	1	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.04	1	0
Leucocythaemia [description not available]	2.04	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.04	1	0
Cancer of Prostate [description not available]	2.44	2	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.44	2	0
Anasarca [description not available]	2.05	1	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.05	1	0
Angiogenesis, Pathologic [description not available]	2.05	1	0
Recrudescence [description not available]	3.45	1	1
Epithelial Ovarian Cancer [description not available]	2.07	1	0
Carcinoma, Anaplastic [description not available]	2.07	1	0
Epithelial Neoplasms [description not available]	2.07	1	0
Cancer of Ovary [description not available]	2.07	1	0
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	2.07	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	7.07	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.07	1	0
Muscle Spasm [description not available]	2.03	1	0
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.03	1	0
Spasm An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.	7.03	1	0
Black Fever [description not available]	2.39	2	0
Leishmaniasis, American [description not available]	2.39	2	0
Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.	2.39	2	0
Leishmaniasis, Cutaneous An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.	2.39	2	0
Leishmania Infection [description not available]	2.91	1	0
Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).	2.91	1	0
Chronic Hepatitis [description not available]	2.92	1	0
Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.	2.92	1	0

licochalcone a

Description

Cross-References

Synonyms (51)

Research Excerpts

Overview

Effects

Actions

Treatment

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (6)

Inhibition Measurements

Activation Measurements

Biological Processes (96)

Molecular Functions (47)

Ceullar Components (34)

Bioassays (371)

Research

Studies (239)

Market Indicators

Research Demand Index: 30.14

Study Types

licochalcone a

Description

Related Flora

Cross-References

Synonyms (51)

Research Excerpts

Overview

Effects

Actions

Treatment

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (6)

Inhibition Measurements

Activation Measurements

Biological Processes (96)

Molecular Functions (47)

Ceullar Components (34)

Bioassays (371)

Research

Studies (239)

Market Indicators

Research Demand Index: 30.14

Study Types

Related Drugs (604)

Related Conditions (209)